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Strength training (ST) is considered an intervention of choice for the 
prevention and treatment of sarcopenia.  The insulin-like growth factor 1 protein 
(IGF-I) plays a major role in ST-induced skeletal muscle hypertrophy and strength 
improvements.  A microsatellite repeat in the promoter region of the IGF1 gene has 
been associated with IGF-I blood levels and phenotypes related to IGF-I in adult men 
and women.  To examine the influence of this polymorphism on muscle hypertrophic 
and strength responses to strength training (ST), we studied 67 Caucasian men and 
women before and after a 10-week single leg knee extension ST program.  One 
repetition maximum (1RM) strength, muscle volume (MV) via computed tomography 
  
(CT), and muscle quality (MQ) were assessed at baseline and after 10 weeks of 
training.  The IGF1 repeat promoter polymorphism and three single nucleotide 
polymorphisms (SNP) were genotyped.  For the promoter polymorphism, subjects 
were grouped as homozygous for the 192 allele, heterozygous, or non-carriers of the 
192 allele.  After 10 weeks of training, 1RM, MV, and MQ increased significantly for 
all groups combined (P < 0.001).  However, carriers of the 192 allele gained 
significantly more strength with ST than non-carriers of the 192 allele (P = 0.02).  
There was also a non-significant trend for a greater increase in MV in 192 carriers 
than non-carriers (P = 0.08).  No significant associations were observed for the other 
polymorphisms studied.  Thus, these data suggest that the IGF1 promoter 
polymorphism may influence the strength response to ST.  Larger sample sizes 
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Human muscle strength declines at the rate of ~12-14% per decade after the 
age of ~50 yr. (116,121).  This loss of strength with age is due to many factors, but is 
primarily attributed to a loss of muscle mass (60,167), termed sarcopenia.  Because 
sarcopenia is related to a loss of functional abilities (162), dependency (163), 
increased risk of falls and fractures (4,118), and decreased bone mineral density 
(191), it has negative consequences for the health status and functional abilities of 
older adults.     
 Several interventions have been proposed for the prevention and treatment of 
sarcopenia, but it appears strength training (ST) is the most effective with the least 
negative side effects (15,81).  Large increases in strength and muscle mass can result 
in a relatively short time with ST, but these changes are highly variable (83).  For 
example, in a ST study from our laboratory, 65-75 year old men and women varied in 
their strength increases from 5 – 59% (5 – 86 lbs.) and muscle volume (MV) 
increases from 1 – 20% (19 – 344 cubic cm) (83,109).  This variation in muscle 
adaptation to training may suggest a genetic influence.  Further support for genetic 
associations come from twin studies showing > 50% of the variance in baseline 
strength and lean body mass is heritable (20,57,143,190).  Adaptation of muscle to ST 
has also been shown to be highly heritable (200,201).  Yet, there is little information 
on how specific polymorphisms may affect this response.   
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Circulating levels of insulin-like growth factor 1 protein (IGF-I) decline with 
advancing age and IGF-I is thought to be causally related to the loss of muscle mass 
and strength that occurs with age (70,205).  Furthermore, exogenous growth hormone 
(HGH) administration increases circulating IGF-I  levels, which has been shown to 
increase muscle mass and possibly strength (30,185).  Studies with transgenic mice 
have shown a direct autocrine/paracrine effect of increased levels of IGF-I expression 
increasing skeletal muscle mass (52).  This same transgenic line of mice, when 
compared to controls, shows reduced age-related losses of skeletal muscle motor 
neurons and type IIB muscle fibers (127).  This preservation of motor neurons and 
fast twitch fibers is likely to preserve strength in aging muscle.  In addition, Boonen 
et al. (16) observed an  increase in muscle strength in older women following  
recombinant-human IGF-I administration.  
   Due to their known association with muscle hypertrophy, genes coding for 
proteins that regulate or are regulated by growth hormone or its mediators (IGF-I and 
II) are prime candidate genes for influencing muscle mass and strength.  Indeed, a 
report from the HERITAGE Family Study revealed an association between an IGF1 
gene marker and baseline fat free mass (FFM) (25).  Furthermore, this same marker 
has been shown to be linked and associated with the change in FFM due to exercise 
training (25,198).  However, the training modality used in the HERITAGE study (25) 
was one that is not commonly associated with significant increases in FFM.  
Nevertheless, an area near the IGF1 gene locus was implicated in these studies for 
influencing FFM both at baseline and in response to training, thus making it a strong 
candidate gene for muscle mass, as well as strength.    
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Recent studies have shown that a CA dinucleotide repeat polymorphism in the 
promoter region of the IGF1 gene can affect blood levels of IGF-I 
(58,99,132,169,177,214,216).  Other CA repeats near gene promoters have been 
shown to alter gene expression in rats and humans (2,181).  The polymorphism in the 
IGF1 gene is typically between 16 and 22 CA repeats and is commonly referred to by 
the base pair length of the amplified DNA fragment (e.g. 192 bp).  Homozygosity for 
the 192 allele (19 CAs at nucleotide position 1087-1127 in the human IGF1 DNA 
sequence Genbank accession number AY260957) has been associated with decreased 
blood levels of IGF-I and decreased bone mineral density (177).  At least two other 
studies support the possible influence of the 192 allele on decreasing blood levels of 
IGF-I (58,169); whereas, others show significantly higher blood levels of IGF-I in the 
presence of the 192 allele (99,132,214).  While the functionality, if any, of this 
polymorphism remains unknown, it appears that it may be associated with the 
functional properties of and phenotypes related to IGF1.  To date, the tissues studied 
in relation to this polymorphism have been of the type to be primarily affected by the 
endocrine action of IGF-I.  Skeletal muscle, however, is known to be affected by the 
autocrine/paracrine action of IGF-I, making it a unique tissue in this respect.  Yet, 
even with the known effects of IGF-I on muscle, this polymorphism has never been 
studied in relation to skeletal muscle phenotypes.   
It is possible that the 192 polymorphism is in linkage disequilibrium with 
another functional polymorphism, thus resulting in the associations seen in the 
aforementioned studies.  Although, no nonsense, missense, or functional 
polymorphisms have been identified for the IGF1 gene (165), recently identified 
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polymorphisms in IGF1 may serve as useful candidate markers for phenotypes related 
to expression levels of IGF1.  Because of the relationships described above between a 
polymorphism in IGF1 and expression levels of the IGF-I protein and between the 
IGF-I protein and muscle function and muscle motor neurons, we hypothesize that 
IGF1 genotype will influence skeletal muscle strength and mass response to ST.   
 Although there are preliminary data from our laboratory to support this 
hypothesis, no published studies have examined this relationship.  Understanding this 
relationship could eventually lead to individualized exercise prescriptions for older 
adults.  Therefore, it is the purpose of this study to determine whether IGF1 genotype 
in the promoter region, or in three recently identified SNPs within the IGF1 locus, 
influence muscle strength and hypertrophy in response to ST in middle-aged and 
older Caucasian men and women.   
METHODS 
Subjects: Healthy, inactive Caucasian men (n = 32) and women (n = 35) 
volunteers between the ages of 52 and 83 yr. were recruited through local senior 
newspaper advertisements and bulk mailings.  A portion of the subjects (n=18) in this 
investigation are from a cohort that had already been studied in our laboratory prior to 
this study (83).  All subjects from both cohorts underwent a phone-screening 
interview, received medical clearance from their primary care physician and 
completed a detailed medical history prior to participating in this study.  Only those 
who had not exercised more than once a week during the six months prior to the study 
were allowed to participate.  All subjects from both cohorts were nonsmokers, and 
were free of significant cardiovascular, metabolic, or musculoskeletal disorders that 
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would affect their ability to safely perform heavy resistance exercise.  After all 
methods and procedures were explained, the subjects read and signed a written 
consent form, which was approved by the Institutional Review Board of the 
University of Maryland, College Park.  All subjects were reminded throughout the 
study not to alter their regular physical activity levels or dietary habits for the 
duration of the investigation. 
Genotyping of (CA) microsatellite within the IGF1 promoter: Genomic 
DNA was prepared from EDTA-anticoagulated whole blood samples by standard 
salting-out procedures (Puregene DNA Extraction, Gentra Systems Inc.). The 
microsatellite was amplified by PCR of genomic DNA using fluorescence-tagged 
primers.  Previously published PCR primers (177) flanking the CA polymorphism 
were used with the forward primer FAM-labeled: 5'-GCTAGCCAGCTGGTGTTATT 
-3' (sense) and 5'-ATGGGAAGAGGGTCTCACCA-3' (antisense).  
Standard polymerase chain reactions were performed on a PTC-100 Thermal 
Cycler (MJ Research, Inc.), annealing steps of 1.0 min at 37oC, and elongation steps 
1.0 min at 72oC for 35 cycles was standardized for PCR reactions.  All PCR reactions 
were carried out in a 25 microliter volume containing ~20 ng of genomic DNA 
template, 14.15 ml dH2O, 2.5 ml 10X PCR buffer, 4.0 ml 1.25 mM dNTP, 0.375 ml 
forward primer (20 µM), 0.375 ml reverse primer (20 µM), 0.1 ml Taq DNA 
Polymerase (5 U/ml), and 1.5 ml of 25 mM MgCl2).  Following amplification, 
samples were diluted with distilled, deionized water and mixed with deionized 
formamide and 1 U internal size standard labeled with ROX fluorescent dye 
(Genescan-500, PE Applied Biosystems), then denatured at 90°C for 2 minutes and 
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immediately transferred onto ice.  Samples were electrophoresed through a capillary 
on the ABI 3100 DNA sequencer (PE Applied Biosystems, Foster City, Calif).  The 
ABI Genescan/Genotyper 2.5 software programs (PE Applied Biosystems) were used 
to determine repeat length of each microsatellite by comparison with the calibration 
curve of the internal standard.  Genotypes of three homozygotes were verified via 
direct sequencing on the ABI 3100.  Additionally, positive controls were used during 
the sequencing runs.  As previously reported, use of the forward primer results in the 
PCR product appearing four bases shorter than actual size; therefore, a correction 
factor was applied (177).  Briefly, use of the forward primer resulted in PCR bands 
that moved through the gel at the rate of a band four base pairs shorter than actual 
size.  This was confirmed by direct sequencing and was consistent throughout all 
samples.  Therefore, four bases was added to the genotyping of each PCR product 
(i.e. 188 + 4 = 192 which = 19 CA repeats). 
Subject genotypes are based on the PCR fragment length, which represents the 
actual number of CA repeats present at this locus, typically 16-27.  The convention 
for reporting the genotype of the IGF1 promoter is based on the PCR fragment length, 
which was variable depending on the number of repeats (e.g., 19 CA repeats = 192 
base pairs) (177).  Thus, PCR base pair length number was reported to remain 
consistent with existing conventions.  
PCR and RFLP genotyping for SNPs:  All PCR reaction mixtures were run 
in a PTC 100 thermal cycler (MJ Research) using standard conditions.  Templates 
were ~20 ng of genomic DNA, annealing steps were 1.0 min and elongation steps 30 
sec at 72oC.  Standard polymerase chain reactions were carried out in a 25 microliter 
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volume containing ~20 ng of genomic DNA template, 14.15 ml dH2O, 2.5 ml 10X 
PCR buffer, 4.0 ml 1.25 mM dNTP, 0.375 ml forward primer (20 mM), 0.375 ml 
reverse primer (20 mM), 0.1 ml Taq DNA Polymerase (5 U/ml), and 1.5 ml of 25 
mM MgCl2.  All primers were designed based on SNP location and ordered from IDT 
DNA technologies.  Primers and annealing temperatures are listed in Table 6.  All 
PCR amplification checks were performed in 2% agarose gels until optimized.  
Restriction enzymes were selected for each SNP by Webcutter 2.0 and 
purchased from MBI Fermentas.  All digests were run according to manufacturers’ 
recommendations.  Restriction enzymes and digestion temperatures are listed in table 
6.  Briefly, The 19779 PCR fragment was digested in a 20 microliter dilution of 2 
units of enzyme, 2.0 µl of manufacturers standard buffer, 2.8 µl of dH20, and 15 µl of 
the PCR product.  All digests were allowed to proceed overnight and were run on a 
2% gel after 24 hours, with the exception of 40395, which was run on a 4% gel to 
achieve optimal separation of bands.  Two independent investigators determined 
genotypes.  Direct sequencing of three PCR products from each SNP was performed 
to verify genotypes.  
Body Composition Assessment: Body weight was determined to the nearest 
0.1 kg with subjects dressed in medical scrubs, and height was measured to the 
nearest 0.1 cm using a stadiometer (Harpenden, Holtain, Wales, UK) and BMI was 
calculated (kg/m2). 
Dual-energy x-ray absorptiometry (DXA): Body composition was 
estimated by DXA using the fan-beam technology (model QDR 4500A, Hologic, 
Waltham, MA).  A total body scan was performed at baseline and again 24 to 48 
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hours after the final session of the single leg ST program.  A standardized procedure 
for patient positioning, attire and utilization of the QDR software was used. Briefly, 
subjects would lie supine on the scan table with their arms at their sides, their palms 
pronated and flat on the table, and their body straight on the mat, as gauged against 
the center lines at the head and foot ends of the mat.  The subject’s feet and thighs 
were slightly separated tilted inward and taped, to prevent movement and insure 
consistency from scan to scan.  Total body FFM, fat mass, and % fat were analyzed 
using Hologic’s version 8.21 software for tissue area assessment. Total body FFM is 
defined as lean soft tissue mass plus total body bone mineral content (BMC).  The 
coefficients of variation for all DXA measures of body composition were calculated 
from repeated scans of 10 subjects who were scanned three consecutive times with 
repositioning (FFM CV < 1%, % Body fat CV = 1.0%).  The scanner was calibrated 
daily against a spine calibration block and step phantom block supplied by the 
manufacturer.  In addition, a whole body phantom was scanned weekly to assess any 
machine drift over time.  
  One repetition maximum (1RM) strength test: The 1RM (i.e. the highest 
resistance at which one repetition could be successfully completed) strength test was 
assessed in the knee extensors before and after training. Three low resistance 
familiarization-training sessions were conducted prior to baseline 1RM strength 
testing, so that subjects would be familiar with the equipment and proper exercise 
techniques.  In addition, this procedure was used to help to control against both large 
initial gains in strength occurring due to motor learning and to help to prevent 
injuries. After the three familiarization training sessions and before the regular 
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training sessions began, knee extensor 1RM strength of each leg individually was 
assessed on the training apparatus (Keiser A-300 Leg Extension machine). After a 
warm-up consisting of 2-3 min of light cycling, subjects were positioned with a pelvis 
strap (seat belt) to minimize the involvement of other muscle groups. Based on 
observations during the orientation period, age, body weight, and data from our 
previous studies, the knee extension 1RM test started with a resistance level estimated 
to be about 20 to 30% of each subject’s predicted 1 RM.  After ~ 60 s of rest upon a 
successful completion of a repetition, subsequent trials were performed at 
progressively higher resistance levels, to minimize the total number of trials required 
before the true one repetition maximum value was obtained. Approximately the same 
number of trials was used for the after training test as was used for baseline testing. 
All aspects of measuring 1-RM strength before and after 10 weeks of single leg 
training were standardized for each subject, including specific seat adjustments, body 
position, and level of vocal encouragement.  
Muscle Volume:  To quantify quadriceps MV, computed tomography (CT) 
imaging of the trained and untrained thighs was performed (GE Lightspeed Qxi, 
General Electric, Milwaukee) at baseline and during the last weeks of the 10-week 
unilateral ST program.  Axial sections of both thighs were obtained starting at the 
most distal point of the ischial tuberosity down to the most proximal part of the 
patella while subjects were in a supine position.  Measurements of MV in the 
untrained leg served as a control for seasonal, methodological, and biological 
variation of MV, by subtracting the changes in the control leg from the training-
induced changes in the trained leg .  Section thickness was fixed at 10 mm, with 40 
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mm separating each section, based on previous work in our laboratory by Tracy et al. 
(207).   Quadriceps MV was estimated based on using a 4 cm interval between the 
center of each section.  Each CT image was obtained at 120 kVp with the scanning 
time set of 1 s at 40 mA.  A 48-cm field of view and a 512 X 512 matrix was used to 
obtain a pixel resolution of 0.94 mm.  Two technicians performed analyses of all 
images for each subject using Medical Image Processing, Analysis, and Visualization 
(MIPAV) software (NIH, Bethesda).  Briefly, for each axial section, the cross-
sectional area (CSA) of the quadriceps muscle group was manually outlined as a 
region of interest.  The quadriceps CSA was manually outlined in every 10 mm axial 
image from the first section closest to the superior border of the patella to a point 
where the quadriceps muscle group is no longer reliably distinguishable from the 
adductor and hip flexor groups.  The same number of sections proximal from the 
patella was measured for a particular subject before and after training, to ensure 
within subject measurement replication.  Investigators were blinded to subject 
identification, training status, and genotype, for both baseline and after training 
analysis.  Repeated measurement coefficient of variation was calculated for each 
investigator based on repeated measures of selected axial sections of one subject on 
two separate days.  Average intra-investigator CV was 1.7% and 2.3% for 
investigator one and two respectively.  The average inter-investigator CV was 3.8%.  
Final MV was calculated with the use of a truncated cone formula as reported by 
Tracy et al. (207) and described by Ross et al. (180).  Calculation of MQ was strength  
(kg) / MV (cm3). 
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Training Program: The training program consisted of unilateral (single leg) 
training of the knee extensor of the dominant leg, three times per week, for 
approximately 10 weeks. Training was performed on a Keiser A-300 air powered leg 
extension machine that allows ease of changing the resistance without interrupting the 
cadence of the exercise. The untrained control leg was kept in a relaxed position 
throughout the training program.  
 Prior to the regular training sessions, subjects underwent three familiarization 
sessions during which they completed a typical training sequence with little or no 
resistance. Subjects would warm-up on a bicycle ergometer for ~ two min prior to 
each training session. The training consisted of five sets of knee extension exercise 
for those < 75 yrs of age and four sets for those > 75 yrs of age.  The protocol was 
designed to include a combination of heavy resistance and high volume exercise.  The 
first set was considered a warm-up and consisted of five repetitions at 50% of the 
1RM strength value. The second set consisted of five repetitions at the current 5RM 
value. The 5RM value was increased continually throughout the training program to 
reflect increases in strength levels.  The first four or five repetitions of the third set 
were performed at their current 5RM value, then the resistance was lowered just 
enough to complete one or two more repetitions before reaching muscular fatigue. 
This process was repeated until a total of 10 repetitions were completed. This same 
procedure was then used in the fourth and fifth sets, but the total number of 
repetitions increased in each set. The fourth set consists of four or five repetitions at 
the 5RM resistance followed by 10 more repetitions for a total of fifteen repetitions 
carried out in the same manner as described above for the 10 repetition set. The fifth 
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set consisted of four or five repetitions at the 5RM resistance, followed by 15 more 
repetitions for a total of 20 repetitions performed in the same manner as the other sets. 
This procedure allowed subjects to use near maximal effort on every repetition while 
maintaining a relatively high training volume. The second, third, fourth, and fifth sets 
are preceded by rest periods lasting 30, 90, 150, and 180 seconds, respectively. The 
shortening phase of the exercise took ~ two seconds, and the lengthening phase took 
~ three seconds.  Subjects performed supervised stretching of the knee extensors and 
hip flexors following each training session. 
Statistical Analyses: All statistical analyses as described below were 
performed using SAS software (SAS version 8.2, SAS Institute Inc., Cary NC).  All 
analyses were conducted on the change values in the dependent variables.  For MV, 
the change value was calculated by taking the difference between the change (pre to 
post training) in MV of the untrained leg and the change in MV (pre to post training) 
of the trained leg.  For strength, the change in 1RM value of the trained leg was used 
as a dependent variable.  Muscle quality was calculated as 1RM kg / MV cm3 and the 
change in the trained leg, was used as the dependent variable of MQ.  The IGF1 
promoter polymorphism was categorized as previously reported in the literature as 
192 homozygotes, 192 heterozygotes, or non-carriers of the 192 allele. 
To examine the effect of the promoter genotype on response to ST, an analysis 
of covariance was used for each dependent variable (DV).  The three levels of the 
predefined groupings of genotype at the IGF1 promoter locus was defined as the 
fixed effect.  To reduce error variance and increase precision, covariates were 
included in the model.  Age and gender were included in all models and baseline 
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values of the dependent variable were included in each model (i.e. baseline value of 
1RM of the trained leg was the covariate for the analysis of strength).  Preplanned 
comparisons of 192 carriers versus non-carriers and 192 homozygotes versus 
heterozygotes and non-carriers were analyzed for each DV.     
The single nucleotide polymorphisms were analyzed separately due to a 
smaller sample size as DNA from 18 subjects was unavailable for SNP genotyping. 
Due to this smaller sample size and distribution of the three genotype groups, 
genotype groups with less than two data points (any genotype with one or no 
subjects) were not included in the analysis.  One 2x2x3 reduced model factorial 
ANOVA for each of the DV’s muscle strength and MV was analyzed.  The factorial 
model included main effects and two-factor interactions only, to reduce the total 
number of comparisons and provide interpretable results.  The two levels of the 
19779 and 40395 loci, and three levels of the 82686 loci genotypes form the factorial, 
and dependent variables were calculated as described for the promoter analysis.  Age, 
gender, and baseline values were included as covariates in the factorial ANOVA as 
described for the promoter analysis.  Post-hoc comparisons were made comparing all 
main effects by LSD post-hoc analysis and significance was accepted when P < 0.05 
for all analyses.  
Hardy-Weinberg equilibrium:  The IGF1 genotype distribution was evaluated 
for conformity to Hardy-Weinberg equilibrium using a chi-square test. 
Power analyses:  Statistical power for the three primary comparisons was 
estimated for the 192 genotype effect on each variable.  This analysis was done using 
data from a study in our laboratory, which employed a similar training and testing 
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protocol.  Statistical power for changes in strength a-priori was estimated to be > .80 
with alpha set at 0.05 (critical effect size MV = .4, 1RM = .45) and accounting for 
present sample size and genotype distribution.  While for MV power was estimated to 
be ~ .60 due to the smaller training-induced critical effect size.   
 
RESULTS 
  Genotype:  IGF1 promoter allele and genotype frequencies (Table 1)  did not 
differ significantly from Hardy-Weinberg expectations and were similar to those 
reported previously (132,177,214).  Likewise, IGF1 SNP allele and genotype 
frequencies did not differ significantly from Hardy-Weinberg expectations (Table 2).  
IGF1 gene characterization including D-prime and haplotype analysis are included in 
Appendix B.  Briefly, only loci 19779 and 40395 were in significant linkage 
disequilibrium with an approximate D-prime of .52 (P < 0.05). 
  Subject characteristics:  One female subject’s 1RM value from the 192 
homozygote group was lost prior to data analysis therefore, her strength values were 
not included in any analysis.  Due to stringent CT scan inclusion criteria, seven 
subjects were not included in CT analysis (four 192 homozygotes (three females and 
one male) and three 192 heterozygotes (two females and one male)).  Body mass, 
percent body fat, and FFM for all subjects did not change significantly as a result of 
training (Table 3).  There were no significant differences in age, height, body mass, 
percent body fat, or FFM at baseline or in response to training among the three IGF1 
promoter genotype groups (Table 4).     
 - 15 - 
  1RM strength:  The 1RM strength of the trained leg did not differ significantly 
at baseline among IGF1 promoter genotype groups when co-varied for sex and age.  
The 192 carriers increased their 1RM strength (14.9 ± 1.4 kg) significantly more than 
non-carriers (9.3  ± 1.8 kg) when co-varied for sex and age (P < 0.05; Table 5; Figure 
1), but all groups increased significantly with training (P < 0.01).  There was no 
significant difference between 192 homozygotes and non-homozygotes for change in 
1RM.  In response to training, SNP ANCOVA main effects and two-factor 
interactions revealed no significant differences in the change of 1RM strength 
(Appendix A).  
  Muscle volume and muscle quality:   Muscle volume increased (i.e., increases 
in trained leg minus changes in untrained leg) in all groups (192 homozygotes, 
heterozygotes, and non-carriers) in response to training (P < 0.01).  Muscle volume 
and muscle quality did not differ significantly at baseline or in response to training 
among IGF1 promoter genotype groups when co-varied for sex and age (Table 5; 
Figure II).  However, training-induced increases in MV for 192 carriers (132 ± 12 
cm3) approached significance for being greater than the increases in non-carriers (94 
± 18, P = 0.08). The 192 homozygotes were not significantly different from the 
heterozygotes and non-carriers in MV or MQ response to training.  Moreover, there 
were no significant differences in MV responses to training among any SNP main 
effect and two-factor interactions.  
   
DISCUSSION 
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    To our knowledge, this is the first study to examine the influence of IGF1 
genotype on strength and MV responses to ST.  These results support our hypothesis 
that IGF1 genotype influences the strength response to ST, but do not support our 
hypothesis of a similar influence on MV and MQ responses to ST in healthy older 
adults.  However, the genotype association with MV response to training approached 
significance.   
  Strength training appears to be the intervention of choice for the prevention and 
treatment of sarcopenia, based on efficacy and safety concerns with other 
interventions (5,23).  IGF-I has been implicated in the loss of muscle with age (70) 
and  IGF-I expression levels change as a consequence of ST in older adults (49).  The 
results of this study add to this literature by showing that carriers of the 192 allele at 
the IGF1 locus have greater strength gains than non-carriers with ST.  
  Although no previous studies have examined the association of the IGF1 gene 
promoter polymorphism with skeletal muscle phenotypes, IGF1 transgenic expression 
and exogenously administered IGF-I protein have been shown to increase skeletal 
muscle size and function (16,138).  Additionally, muscle stimulation (mechanical, 
electrical, and stretch) increases IGF-I protein and overall protein content in skeletal 
muscle and produces significant increases in muscle size and strength 
(37,49,123,224).  The increase in IGF1 mRNA has been reported to be proportional 
to the increase in muscle strength in elderly adults following ST (49).  Thus, it seems 
that increases in IGF1 expression may be causally related to increases in muscle size 
and strength.  In the study by Fiatarone et al. (49), IGF1 mRNA increased by an 
average of ~500% in response to ST in the elderly.  However, the variation in IGF1 
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mRNA expression was more than 500%, suggesting a substantial inter-individual 
variability in response to training.    
  Indeed, IGF-I blood levels, muscle size and function are known to be highly 
heritable traits (20,80,92,190,204).  IGF-I blood levels are highly heritable in 
children, middle-aged, and elderly adults (80,92).  In a study of twin children 
comparing IGF-I plasma levels, monozygotic pairs had a within-pair correlation of r 
= 0.91 and dizygotic pairs of  r = 0.40 (92).  When middle-aged and elderly twins 
were compared for IGF-I plasma levels, the heritability was found to be less than 
previously reported, but still quite high at 63% (80).  Thus, it appears that at least 
plasma levels of IGF-I are under considerable genetic influence, though this influence 
may decrease with age.  In this regard, a study examining the same CA repeat IGF1 
promoter polymorphism as the one in the current study, demonstrated a significant 
age related decline in circulating IGF-I levels, which was associated with  this 
polymorphism (169).  Consistent with our findings, this would suggest an influence 
of the IGF1 promoter polymorphism on phenotypes that may be affected by IGF1 
expression. 
  The hypothesis that genetic factors may influence muscular strength is 
supported by data from both animals (14) and humans (168,201,204).  Support from 
animal studies comes from Biesiadecki et al. (14) who observed a 1.5 to 5.2-fold 
divergence between the muscular strength of male rat strains with the lowest and 
highest strength levels and support from human studies come from Reed et al. (168) 
who observed significant genetic effects for absolute grip strength and grip strength 
normalized for body weight in 127 identical and 130 fraternal twin pairs.  In the latter 
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study, it was estimated that genetic factors accounted for 65% of the variance in grip 
strength, even after adjusting for the effects of weight, height, and age (168).  In 
younger men, Thomis et al. (201) reported that up to 82% of the variance in strength 
was explained by genetic factors.  Tiainen et al. (204) examined the strength of the 
knee extensors (same muscle group tested in the current study) in an older population 
and attributed 31% of the variance to genetics factors.    
  To our knowledge, only two studies have attempted a genome-wide search for 
genes related to phenotypic measures of muscle (24,25).  In one of these studies fat 
free mass, measured by hydrostatic weighing, showed significant linkage with the 
IGF1 receptor polymorphism in the Quebec Family Study (24).  In the HERITAGE  
Family Study, baseline FFM and the change in FFM due to exercise training both 
showed evidence of significant linkage with the CA repeat IGF1 promoter 
polymorphism examined in our current study (25).  Additionally, linkage and 
association of baseline FFM and the change in FFM due to exercise training has been 
demonstrated with the IGF1 promoter polymorphism (198).  Although the training 
modality used in the HERITAGE study is not usually associated with large changes 
in FFM, it appears that a polymorphism in the IGF1 gene may be associated with 
changes in FFM.  Likewise, we have demonstrated an association of this 
polymorphism with muscle function (strength) response to training, which is believed 
to be under the autocrine/paracrine influence of IGF1.  
  We are aware of only three studies that have examined the influence of genetic 
factors on skeletal muscle phenotypic response to ST (56,200,201). Thibault et al. 
(200) studied ST responses of five monozygotic twin pairs and found no significant 
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interaction between strength response to training and heredity, which is not surprising 
given their small sample size.  Thomis et al. (201) found evidence for a significant 
role of heredity in strength responses to ST.  These responses were independent of the 
influence of genetic factors on baseline strength values.  However, Folland et al. (56) 
was the only study that examined the effects of a specific candidate gene 
polymorphism on strength or muscle mass response to training.  They reported a 
significant relationship between the ACE genotype and strength response to ST (56). 
     The IGF1 promoter polymorphism has been examined in numerous contexts 
(58,99,169,177).  As in the current study, genotyping of the microsatellite is typically 
separated into three groups, 192 homozygotes, 192 heterozygotes, and non-carriers of 
the 192 polymorphism.  Whether the 192 polymorphism is causally related to changes 
in IGF1 function is not known; yet, the 192 allele is the most prevalent allele in the 
majority of the populations studied to date.  Additionally, there is evidence in animals 
and humans that CA repeats found in gene promoter regions can affect gene 
expression (2,181).  It has been suggested by King (29) that these repeats act as 
evolutionary tuning knobs to fine-tune gene expression with minor deleterious 
consequences.  Furthermore, genome-wide scans and linkage studies have implicated 
this allele (192) in phenotypes known to be affected by IGF-I (25,35,198).   
  As mentioned, the functionality of this polymorphism is not currently known.  It 
is possible that length of the polymorphism could be affecting expression levels or 
that this polymorphism is in linkage disequilibrium with a functional polymorphism 
that affects phenotypes related to IGF1 expression.  Based on the genome-wide scans 
that have been reported associating this polymorphism with IGF1 related phenotypes 
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it appears that it is at least a marker for IGF1 related phenotypes.  To address the 
functionality of this polymorphism in-vivo in humans, IGF1 expression levels would 
be needed along with a large sample size of individuals who are homozygous for this 
allele.  Alternatively, a cell culture system could be used to address this in-vitro.  
Therefore in light of the current lack of data on functionality, the conventional 
grouping of 192 carriers and non-carriers was used as previously reported in the 
literature. 
  Rosen et al. (177) first implicated this polymorphism with serum levels of IGF-I 
and BMD in a study examining older men and women (177).  It was reported that 192 
homozygotes had lower blood levels of IGF-I; additionally, and in a group of older 
men, 192 homozygotes made up a disproportionately large number of those with 
idiopathic osteoporosis (177).  The reports by Frayling et al. (58) and Rietveld et al. 
(45) concur with Rosen’s findings of decreased blood levels of IGF-I in carriers of the 
192 allele.  In a cross-sectional study of young men and women, Frayling et al. (58) 
reported that 192 carriers had decreased blood levels of IGF-I, although no other 
associations were found.  The study by Rietveld et al. (45) of older men and women, 
reported an age- related decline in blood levels of IGF-I in 192 homozygotes.  In 
contrast to Rosen’s findings, subsequent studies have demonstrated that 192 non-
carriers have lower IGF-I blood levels and are more likely to be osteoporotic 
(99,171).  Additionally, a longitudinal study by Missmer et al. (36) in middle-aged 
and older men and women reported a lower level of IGF-I in control subjects who 
were non-carriers of 192.  Similarly, Vaessen et al. (214) concluded that non-carriers 
had decreased blood levels of IGF-I and an increased risk for type II diabetes and 
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myocardial infarction.  Finally, Kim et al. (99) reported 192 homozygotes as having 
the highest blood levels of IGF-I in Korean women.   
  Some reports have concluded that the 192 allele has no effect on blood levels of 
IGF-I or only has an effect when combined with oral contraceptive use (89,230).  Yet 
both of these studies found an association with a measured phenotype, breast cancer, 
or the interaction of blood levels with oral contraceptive use and the 192 allele.  There 
have been two reports of the 192 allele showing no association with IGF-I blood 
levels or any measured phenotype (3,34).  Although conclusive determination of the 
effect of the 192 genotype from the aforementioned studies is difficult, it seems that 
the IGF1 192 allele is at least associated with some phenotypes related to IGF1 
expression.  Skeletal muscle is known to significantly increase IGF1 expression levels 
and produce unique isoforms of IGF-I in response to ST (49,123).  Yet, none of the 
previous studies has examined phenotypes related to skeletal muscle.  In the present 
study, we report the first intervention study to examine the influence of the 192 allele  
on muscle phenotypes known to be related to IGF1 expression.   
  Some limitations of the current study are the lack of IGF1 expression data for 
muscle, the use of only one ethnic group, and the statistical power for muscle volume.  
The use of one ethnic group was decided upon to control for the possible varying 
affects this polymorphism might have in different ethnic (genetic) backgrounds and 
because it has been shown that the prevalence of the 192 allele differs with ethnicity 
(34).  We are currently examining this relationship in African Americans.  The 
inconclusive results in MV of the present study may be due to a lack of statistical 
power.  The statistical power to detect the genotype difference in MV was ~.60, while 
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for strength it was > .85.  This is primarily due to the smaller (as compared to 
strength) effect size seen in MV in response to ST.  Additionally, the design of the 
current study may have reduced MV effect size by the use of an untrained control leg.  
The control leg reduced the absolute change seen in response to ST yet allowed for a 
more precise determination of the change that could be attributed to ST or genetics by 
reducing the likelihood that extraneous factors would affect our dependent variable of 
MV.  Thus, future studies should consider changes in muscle mass or MV with a 
larger sample size and the use of a control leg or group, consider using other ethnic 
groups, and where the muscle biopsy technique is available, measure mRNA and/or 
protein levels of IGF-I. 
  In conclusion, this is the first study to examine the effects of the IGF1 promoter 
polymorphism on muscle phenotypic responses to ST in older adults.  The results 
suggest that in response to ST, carriers of the 192 allele will have a greater increase in 
strength and possibly muscle volume when compared to non-carriers.  The results of 
the current study, in combination with future studies, will continue to contribute to 
the understanding of the role of gene polymorphisms on the responses to exercise 
training. 
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Table 1. IGF1 CA promoter allele and genotype frequency 
 
Number of CA repeats     Total (%)       Men              Women 
 
 
< 17          1 (<1)      0        1 
  
   17          3   (2)      2        1 
   18           8   (6)      5        3 
   19         82 (62)               38      44  
   20         27 (20)               12      15 
   21         12  (9)                 6        6 
   22          1  (<1)      1        0 
 
Range          6 – 22            17 – 22    6 – 21 
 
Genotype         
 
19/19   (192/192)        24 (36)              10                                   14 
19/ -- (192/ --  )        34 (51)   18                                   16 
-- / --    (non-carrier)                     9 (13)     4         5 
         
 
 
Table 2. IGF1 SNP allele and genotype distribution of all subjects. 
 
         Allele frequency                     Genotype frequency 
        T     C        A     G            TT   TC   CC         AA   AG  GG 
 
19779     .78    .22        --      --          .59   .37    .04           --       --      --  
 
40395                             --       --       .79     .21         --       --      --          .61    .35     .04 
 
82686                             --       --       .39    .61          --       --      --          .19    .40     .40 
 
 - 24 - 
22
Table 3. Physical characteristics for all subjects 
 
                   Men (n=32)                                     Women (n=35) 
                  Baseline               After Training                             Baseline               After Training 
Age (yrs)                                       70 (6)                     --                              67 (8)                   -- 
   
Height (cm)                                169 (6)                    --                                       161 (8)                             -- 
 
Weight (kg)                               83.5 (12.0)                84.0 (12.7)                              71.3 (13.6)                 71.2 (14.13) 
 
Fat (%)                                         29 (5)                       29 (4)                                       39 (5)                         39 (6) 
 
FFM (kg)                                   58.2 (6)                    58.5 (7.1)                                 42.3 (6.1)                   42.3 (5.1) 
 
1RM (kg)                                     74 (14)                      89 (22)                                     45 (8)                         55 (11) 
Values are means and (SD) 




 - 25 - 
-23-
Table 4.  Physical characteristics for subjects by IGF1 promoter genotype 
 
    192 Homozygotes       192 Heterozygotes          All other genotypes 
      Baseline    After Training       Baseline     After Training                  Baseline     After Training 
Age (yrs)              67 ± 1                     --         70 ± 1              --                68 ± 4                  -- 
 
Height (cm)        169 ± 2                     --       167 ± 2              --              165 ± 3        -- 
 
Weight (kg)       78.6 ± 2.5         78.7 ± 2.5                    75.7 ± 2.0         76.3 ± 2.1                         75.8 ± 5.3        76.3 ± 5.6 
 
Fat (%)                34 ± 1                  34 ± 1                       34 ± 1                 34 ± 1                33 ± 2                34 ± 1 
 
FFM (kg)          51.8 ± 1.4          52.0 ± 1.4                  50.0 ± 1.0            50.4 ± 1.0                        50.0 ± 2.2         50.1 ± 2.4 
 
Male/Female (n)   10/14                        --          18/16     --         4/5                  -- 
Values are means ± SE 
FFM = fat free mass 
None of the After Training values were significantly different from baseline 
Weight, % Fat, and FFM are corrected for mean age (68) and sex (50/50 ratio) 
 
25 
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Table  5.   Muscle volume, 1RM muscle strength, and muscle quality measurements before and after training by IGF1 192 CA 
repeat polymorphism. 
 
            192 Homozygotes      192 Heterozygotes              All other genotypes 
                 Baseline     After Training     n=       Baseline     After Training     n=       Baseline     After Training    n= 
          
Trained leg 
Muscle Volume (cm3) 1467 ± 33      1593 ± 37*           20         1362 ± 38      1508 ± 43*          31       1332 ± 74     1438 ± 75*        9                 
 
Muscle Quality            4.18 ± .15      4.76 ± .13*          20         4.40 ± .12       5.02 ± .10*         31          4.27 ± .18      4.6 ± .16*      9               
Kg/cm3(X 10-2) 
 
1RM (kg)                       61 ± 2            76 ± 3*              23              59 ± 2          74 ± 2*             34            57 ± 4          66 ± 4* †       9 
        
 
Untrained leg 
Muscle Volume (cm3) 1415 ± 48      1413 ± 48             20          1306 ± 40      1316 ± 46           31        1322 ± 76     1333 ± 79        9       
 
Muscle Quality            4.18 ± .23      4.58 ± .23         20           4.37 ± .14      4.54 ± .15           31          3.70 ± .29    4.05 ± .24       9                
 (X 10-2)  
 
1RM (kg)                      58 ± 3              63 ± 3               23               57 ± 3             61 ± 3           34              50 ± 5          55 ± 5          9 
  
Values are means ± SE 
*Significantly different than before training, p < 0.01 
† Significantly different than 192 homozygotes and 192 heterozygotes, p < 0.05 
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Table 6. Sequences of PCR primers used for amplification and sequencing of IGF1 gene SNPs 
                
SNP         Forward Primer        Reverse Primer        Annealing Restriction enzyme/  
                      temp (C)   digestion temp (C) 
 
19779    5’-CAGATTTGTGGCACTAATAC        5’-CTATTAAAGGGATGACTGTG     49°        EcoRI / 37° 
40395    5’-AAGTTAAGAAGCAGTGTTGC       5’-AGTGGTGCAATTGTGGCTCA     55°          AluI /  37° 
82681    5’-ACATACAGGTTCTGTGGAAT        5’-GTTGGAGAGGATTATGTGTT     51°         TaiI  /  65° 
 
SNP numbering represents nucleotide position in the human IGF1 DNA sequence. 
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Fig 1. 

























Figure 1. The absolute change in 1RM strength corrected for age and sex for each IGF1 
promoter genotype group after 10 weeks of training.  Carriers of the 192 allele had 
significantly greater gains in strength than non-carriers (* P = 0.02).  Values are means ± 
SE. 
*
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Fig 2. 
Change in quadricep muscle volume with strength 






























Figure 2. The difference between the change in muscle volume of the trained leg and 
control leg for each IGF1 promoter genotype group corrected for age and sex after 10 
weeks of training.  Carriers of the 192 allele did not differ significantly from non-carriers 
in terms of their gain in muscle volume (P = 0.08).  Values are means ± SE. 
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APPENDIX A: SNP SIGNIFICANCE VALUES FOR STRENGTH 
  Significance values for SNP 2-way comparisons of changes in strength 










(kg)   P 
           
TC   24  TT   34  0.25 
 AA  26   AG  32  0.47 
  AA 29    AG 26  0.71 
  AA 29    GG 31  0.86 
  AG 26    GG 31  0.49 
TC AA  21  TC AG  27  0.60 
TC AA  21  TT AA  31  0.32 
TC AG  27  TT AG  36  0.42 
TT AA  31  TT AG  36  0.60 
TC  AA 22  TC  AG 25  0.83 
TC  AA 22  TC  GG 26  0.76 
TC  AA 22  TT  AA 37  0.48 
TC  AG 25  TC  GG 26  0.93 
TC  AG 25  TT  AG 28  0.75 
TC  GG 26  TT  GG 36  0.25 
TT  AA 37  TT  AG 28  0.60 
TT  AA 37  TT  GG 36  0.97 
TT  AG 28  TT  GG 36  0.29 
 AA AA 22   AA AG 30  0.53 
 AA AA 22   AA GG 27  0.68 
 AA AA 22   AG AA 37  0.45 
 AA AG 30   AA GG 27  0.71 
 AA AG 30   AG AG 23  0.46 
 AA GG 27   AG GG 35  0.37 
 AG AA 37   AG AG 23  0.38 
 AG AA 37   AG GG 35  0.93 
 AG AG 23   AG GG 35  0.22 
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APPENDIX B:  






  The human IGF1 gene is located on chromosome 12 (12q22-q23).  The gene is 88 
kb in length and contains six exons and five introns.  Partially due to the inconclusive 
results of the functionality of the IGF1 promoter microsatellite (CA repeat) and due to the 
large size of the IGF1 gene, three SNPs were identified and genotyped in the present 
study to search for an association with skeletal muscle phenotypes.  Although a small 
sample size (n=49) prohibited a haplotype comparison with the measured phenotype, a 
characterization of the SNPs was conducted to describe the association of the three SNPs 
(LD) and to examine the haplotypes at this gene.  This information could be useful to 
identify haplotypes useful in other case/control association studies. 
  A standard measure of the statistical association between a pair of alleles A and B 
at two different loci is known as linkage (gametic) disequilibrium (LD), DAB = (pAB) – 
(pApB).   It is defined as the deviation of the haplotype frequency from that expected at 
CA repeat 




Human IGF1  
88,066 bases 
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linkage equilibrium (random association of alleles).  For a population at linkage 
equilibrium DAB = 0.  If there is no statistical association of alleles in haplotypes, then the 
frequency is equal to the product of the corresponding allele frequencies.  In this case, 
one says that the population is at linkage equilibrium.  The coefficient D can be positive 
or negative depending on whether alleles A and B are in coupling disequilibrium 
(haplotypes AB are overrepresented) or in repulsion disequilibrium (haplotypes AB are 
underrepresented).   
  As mentioned, two loci A and B, are said to be in linkage (gametic) 
disequilibrium if their respective alleles do not associate independently in the studied 
population.  If two genes are independently inherited, expected gametic frequencies, can 
be obtained from allelic frequencies in the population.  The non-randomness of gametic 
frequencies can be quantified by means of a deviation from two locus equilibrium: D is 
the gametic disequilibrium coefficient, or measure of deviation from 2 locus equilibrium.  
The statistical significance of the observed allelic association under the null hypothesis of 
random allelic association can be tested by a chi-square analysis. 
  The EH program (estimate haplotype frequencies) is a soft-ware program to test 
and estimate LD between different markers or between a disease locus and markers 
(199,223).  Each individual in a sample is classified uniquely in terms of his or her two-
locus genotype and.  However, it is often difficult to infer haplotypes from genotype data 
alone.  This is due to the unknown phase of alleles along a chromosome in individuals.  
In individuals who are doubly heterozygous (Aa/Bb) there can be either of two phases, 
AB/ab, or Ab/aB.  These individuals present a difficulty, but omitting them from 
consideration in this analysis can lead to a bias and a loss of information for the test of 
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LD (199).  Methods have been developed to infer haplotype phase via likelihood 
methods, as in the EH program or similar programs (199,217).  These programs utilize 
the EM (expectation maximization) algorithm to resolve phase-ambiguous genotypes 
utilizing data from the studied population to estimate haplotype frequencies.  The EM 
algorithm is a commonly used iterative statistical procedure that uses data parameters 
from an existing population to estimate missing or ambiguous data points.  In this case, 
the EM algorithm resolves the ambiguous haplotypes of double heterozygotes by 
utilizing the known genotype data from this population.   Once all haplotypes are known 
or estimated, a chi-square analysis is performed to determine the likelihood that the 
observed haplotypes would have occurred by chance based on allele frequencies {ott; 
terwilliger}(148,199).  The EH program accomplishes this in two steps, first by 
estimating the frequency of ambiguous haplotypes then by using a chi-square analysis of 
all haplotypes compared to haplotypes that would occur with random association of 
alleles, which will determine statistical significance of LD {terwilliger}(199).  In this 
case, the chi-square statistic has 1 df, because under the hypothesis of allelic association, 
there are three free parameters (haplotype frequencies), whereas under the hypothesis of 
no allelic association, there are only two free parameters (the two gene frequencies).  The 
difference in free parameters is 1, so the distribution has 1 df.  Thus the chi-square 
produces a significance (alpha) value for LD, commonly reported as D or D’ (112,148). 
  The disequilibrium coefficient (D) is the simple measure of linkage 
disequilibrium (DAB = pAB – pApB).  However, erosion of LD occurs over time by 
recombination.  A measure developed by Lewontin, D’, will express the coefficient 
relative to this initial value (1).  In the current study, D’ was calculated in an excel 
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spreadsheet and significance tested by the EH program chi-square analysis (112,199).  
The Chi-square value calculated by the EH program is the test of significance of LD 
between the alleles (148,199).  The results of the current study show that the 19779 and 
40395 SNPs are significantly linked, with a D’ of 0.527 suggesting modest LD between 
these two sites (Chi-square = 12.95, P < 0.05).  The 40395 and 82686 SNP haplotypes 
were not significantly different from what might be expected to happen by chance (chi-
square = 2.39, P = 0.12).  Additionally, the 19779 and 82686 alleles were not in LD (chi-
square = 1.37, P = 0.23)  The 19779 and 40395 loci are located closer to each other than 
the 40396 and 82686, which may partially explain these findings.       
  Additionally, the Phase program was utilized to estimate haplotype frequencies 
for all polymorphisms.  A total of 15 haplotypes were observed, while 27 were possible.  
Though these data do not represent an in-depth analysis, they do suggest that 
recombination has occurred within this gene, more likely near the 3’ end.  This study 
represents a short preliminary analysis of the characterization of this gene, while 
numerous SNPs analyzed independently and as haplotypes and a larger sample size is 
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Haplotype estimations and D prime values for the 19779 and 40395 loci in IGF1 gene. 
Estimates of Gene Frequencies (Assuming Independence)
----\----------------------------
locus \ allele 1 2
--------\------------------------
1 | 0.7800 0.2200
2 | 0.7900 0.2100
---------------------------------
# of Typed Individuals: 50
There are 4 Possible Haplotypes of These 2 Loci.
They are Listed Below, with their Estimated Frequencies:
----------------------------------------------------
| Allele Allele | Haplotype Frequency |
| at at | |
| Locus 1 Locus 2 | Independent w/Association |
----------------------------------------------------
1 1 0.616200 0.702536
1 2 0.163800 0.077464
2 1 0.173800 0.087464
2 2 0.046200 0.132536
----------------------------------------------------
# of Iterations = 8
#param Ln(L) Chi-square
-------------------------------------------------------------------
H0: No Association 2 -79.83 0.00
H1: Allelic Associations Allowed 3 -73.35 12.95
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Haplotype estimations and D prime values for the 40395 and 82686 loci in IGF1 gene. 
 
Estimates of Gene Frequencies (Assuming Independence)
----\----------------------------
locus \ allele 1 2
--------\------------------------
1 | 0.7857 0.2143
2 | 0.3878 0.6122
---------------------------------
# of Typed Individuals: 49
There are 4 Possible Haplotypes of These 2 Loci.
They are Listed Below, with their Estimated Frequencies:
----------------------------------------------------
| Allele Allele | Haplotype Frequency |
| at at | |
| Locus 1 Locus 2 | Independent w/Association |
----------------------------------------------------
1 1 0.304665 0.264313
1 2 0.481050 0.521402
2 1 0.083090 0.123443
2 2 0.131195 0.090843
----------------------------------------------------
# of Iterations = 8
#param Ln(L) Chi-square
-------------------------------------------------------------------
H0: No Association 2 -90.71 0.00
H1: Allelic Associations Allowed 3 -89.51 2.39
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19 = 19 CA repeats 
 
List of estimated haplotype frequencies. 
 
Haplotypes estimated by Phase based on genotypes. 
 
            Haplotype    Frequency  
(Observed) 
         1        18 TAG       6.0 
         2        19 TAA       9.0 
         3        19 TAG     39.0 
         4        19 CAA       1.0 
         5        19 CGA       9.0 
         6        19 CGG       4.0 
         7        20 TAA     13.0 
         8        20 TAG       3.0 
         9        20 TGA       3.0 
        10       20 CAA       1.0 
        11       20 CAG       6.0 
        12       21 TAA       3.0 
        13       21 TGG       3.0 
        14       21 CGA       1.0 
        15       22 TGG       1.0 
 
Expected frequency of haplotypes assuming random association of alleles 
 
     Haplotype        Frequency          SE 
   (Expected) 
         1       18 TAA    0.006678     0.008298 
         2       18 TAG     0.050241     0.009076 
         3       18 TGA     0.000815     0.002707 
         4       18 TGG     0.000795     0.002675 
         5       18 CAG     0.000295     0.001675 
         6       19 TAA     0.116501     0.022571 
         7       19 TAG     0.345778     0.024625 
         8       19 TGA     0.004312     0.008766 
         9       19 TGG    0.005693     0.007927 
        10       19 CAA     0.009287     0.010787 
        11       19 CAG     0.008383     0.008315 
        12       19 CGA     0.076888     0.016437 
        13       19 CGG     0.041003     0.010246 
 - 39 - 
        14       20 TAA     0.111485     0.016532 
        15       20 TAG     0.054389     0.017168 
        16       20 TGA     0.020039     0.011016 
        17       20 TGG     0.003828     0.006544 
        18       20 CAA     0.013045     0.004896 
        19       20 CAG     0.051620     0.007064 
        20       20 CGA     0.000497     0.002150 
        21       21 TAA     0.019629     0.009833 
        22       21 TAG     0.006788     0.008437 
        23       21 TGA     0.002071     0.004429 
        24       21 TGG     0.026060     0.005128 
        25       21 CGA     0.009539     0.008663 
        26       21 CGG     0.004540     0.004889 
        27       22 TGG     0.009214     0.002332 
        28       22 CGG     0.000590     0.002332 
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APPENDIX C: 
Research Hypotheses and Significance of the proposed study  
 
Research Hypotheses 
1. Muscle volume changes, estimated by computed tomography and due to 
strength training, will vary among individuals depending on their IGF1 
geneotype. 
2. Muscle strength changes, estimated by 1RM, due to strength training will 
vary among individuals depending on their IGF1 geneotype. 
3. Muscle quality changes, estimated by measures of muscle volume and 
strength, due to strength training will vary among individuals depending on their 
IGF1 geneotype. 
Significance: 
 Numerous studies to date have found an association of the IGF1 polymorphism 
with blood levels of IGF-I and/or specific health parameters that could be related to the 
production of IGF-I protein.  However, no studies to date have examined the association 
of this polymorphism with changes in muscle volume (due to strength training) which is 
known to be affected by production of IGF-I protein.  The findings of this study may help 
to determine whether variation in the promoter region of IGF-I gene locus has an effect 
on skeletal muscle in response to strength training in older adults.  Furthermore, these 
findings may help to identify individuals who are more vulnerable to the consequences of 
sarcopenia or those more likely to respond to ST.  With this information, and information 
on other genes found to influence sarcopenia, vulnerable individuals may be targeted as 
candidates for strength training, physical therapy, nutritional, or other interventions based 
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on their genetic makeup.  This could allow individualized interventions to maximize 
health benefits in a particular individual. 
 
Delimitations, Limitations & Operational Definitions 
 
Delimitations 
1. The scope of this study will be delimited to 67 men and women between 
the ages of 50 and 85 who volunteer as participants and complete the study 
protocol. 
2. Participation in the study will be limited to healthy participants free of 
musculoskeletal or cardiovascular disease. 
3. Polymorphisms in the regions flanking the 192 polymorphism will not be 
identified or assessed in the genomic material for this study.  It is therefore 
possible that any reported genotype effect is due to linkage disequilibrium 
between the 192 polymorphism and a distinct and putative polymorphism. 
4. Based on previous research subjects will be divided into three groups in 
determining the effect of this genotype.  The groupings will be based on homo- 
and hetero-zygosity for the 192 polymorphism. 
Limitations 
1. The participants will be volunteers and not randomly selected from the 
general population.  Therefore, the results of this study cannot be generalized to 
individuals who do not possess characteristics such as age, body size, physical 
activity, etc. similar to those of subjects in the study. 
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2. Subjects will self-report many factors related to health and lifestyle such 
as physical activity habits, dietary habits, medication regimens, and medical 
conditions.  It is possible that inaccurate self-reports may adversely affect the 
results of this study. 
Operational Definitions: 
IGF-I protein: A polypeptide similar in structure to insulin with 
autocrine/paracrine effects on muscle during growth and differentiation and in 
adult life. 
IGF-I gene: A gene of at least 45 kb containing five exons and four introns.  The 
location of the human IGF-I gene is 12q22–q23. 
192 polymorphism (IGF-I gene):  This polymorphism is identified by the length 
of a CA dinucleotide repeat found in the promoter region of the IGF-I gene.  It 
can be 16 to 22 dinucleotides in length (99% of population) and is located at 
nucleotide position 947–984 in the original human IGF-I DNA sequence Genbank 
accession number M12659, M77496.  
Sedentary: A description for individuals who are not physically active.  In the 
proposed study this term describes individuals who, on average, have exercised 
aerobically for less than 20 minutes per day less than 3 times per week and have 
not performed any type of regular resistance training over the past six months. 
Sarcopenia: A condition characterized by the loss of muscle size, quality, and 
function that occurs with aging.  This typically leads to or exacerbates ailments 
such as osteoporosis and loss of functional independence. 
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Dual-energy x-ray absorptiometry (DXA): A technique for assessing whole and 
regional body composition that considers the body to be composed of three 
compartments: bone mineral mass, soft tissue, and lean tissue.  Tissue amounts 
are based on the attenuation of x-rays as they pass through the body. 
Computed tomography (CT): A technique for assessing regional muscle size 
based on the examination of axial scans of the thigh.  Visual images are created 
from the measurement of the intensity of x-rays and analyzed to measure cross-
sectional area.  The images are based on the attenuation of x-rays as they pass 
through the body.  Attenuation scores are measured in hounsfield units, which 
depend upon the level of absorption of emitted x-ray beams, -1000 air to +1000 
bone.  AT is usually -190 to -30. 
Muscle volume: Muscle volume is an estimate of the volume of the quadriceps 
muscle group and will be determined by the MIPAV software and equations used 
by Tracy (207).  Briefly, this involves an equation that utilizes the 8-10 axial thigh 
slices that are obtained from the CT scan. 
Muscle quality: Also known as specific tension or specific force, is the strength 
of a muscle divided by the cross-sectional area to estimate the amount of force 
production per unit area of muscle tissue.  This has been shown to decrease with 
age and increase with resistance training. 
5-RM: Refers to the maximum amount of resistance an individual can move 
through a complete range of motion only five times 
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APPENDIX D: FORMS 
Consent form 
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Training log 
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Initial telephone interview 
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Medical Clearance 
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1RM data collection form 
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DXA record 
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DXA output 
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APPENDIX E: GENOTYPES 
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category Age  SEX 19779 40395 82686 
        
        
HUR 015 192/194 2 79 F TT AA AG 
HUR 017 190/192 2 80 M TT AA GG 
HUR 018 192/194 2 77 M TT AG AG 
HUR 020 190/194 3 60 F TC AA GG 
HUR 023 192/192 1 61 F TT AA AG 
HUR 025 192/196 2 57 F TC GG GG 
HUR 027 194/194 3 52 F TT AA AA 
HUR 028 192/192 1 64 F TC AG AA 
HUR 030 192/194 2 57 F TC AA GG 
HUR 031 192/192 1 60 F TC AG AA 
HUR 032 190/194 3 54 M TT AG AG 
HUR 033 192/192 1 62 F TC AA AG 
HUR 034 192/192 1 65 F TC AG GG 
HUR 036 192/194 2 75 M TC AA GG 
HUR 038 192/194 2 61 M TT AA GG 
HUR 039 194/194 3 77 M TC AA AA 
HUR 041 192/192 1 63 M TC AG GG 
HUR 047 192/196 2 54 M TT AG GG 
HUR 048 192/192 1 53 F TT AA GG 
HUR 049 192/194 2 77 F TT AA AG 
HUR 052 192/192 1 78 F TT AA GG 
HUR 055 192/194 2 61 F TC AG AA 
HUR059 192/196 2 78 F TT AA AG 
HUR060 192/196 2 76 F TT AA AG 
HUR 062 192/194 2 69 M TT AA GG 
HUR 063 192/196 2 66 M TC AG AA 
HUR 065 192/192 1 65 M TC AG AG 
HUR 066 192/194 2 71 F TT AA  
HUR 068 194/194 3 66 M CC AA GG 
HUR 071 192/192 1 75 M TC AG AA 
HUR 073 192/196 2 72 M CC GG AG 
HUR 074 192/192 1 65 F TT AA GG 
HUR 075 190/192 2 71 M TT AA AG 
HUR 076 192/194 2 59 F TT AG AG 
HUR 077 192/192 1 70 F TT AA GG 
HUR 078 192/192 1 71 M TT AA GG 
HUR 079 192/196 2 72 M TT AG GG 
HUR 080 188/194 3 82 M TT AA AG 
HUR 081 192/194 2 83 F TT AA AG 
HUR 084 194/194 3 81 F TT AA AA 
HUR 085 192/192 1 71 M TC AG AG 
HUR 087 188/192 2 62 M TT AA GG 
HUR 091 192/192 1 61 F TC AG AG 
HUR 092 192/194 2 68 M TC AA AG 
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HUR 093 192/192 1 65 F TT AA AG 
HUR 094 192/194 2 65 F TT AA GG 
HUR 097 192/196 2 85 F TT AG AG 
HUR 098 192/194 2 72 M TT AA AG 
HUR 099 192/192 1 70 M TC AG AA 
1 192/194 2 68 M    
2 190/192 2 71 M    
3 192/198 2 66 M    
4 192/196 2 69 M    
5 190/192 2 71 M    
6 192/192 1 72 M    
7 192/196 2 68 M    
9 192/192 1 72 M    
10 192/192 1 73 M    
11 192/192 1 65 M    
14 190/192 2 67 F    
16 192/192 1 64 F    
18 192/196 2 66 F    
20 192/192 1 71 F    
21 192/192 1 70 F    
22 176/188 3 70 F    
23 194/196 3 66 F    
24 190/192 2 73 F    
                
SD   7.46     
Mean   68.36     

















 cm kg kg %  kg kg 
        
HUR 015 168.5 87.2 86.5 47.64% 46.31% 45.66 46.44 
HUR 017 160.5 65.5 64.6 20.90% 22.93% 51.81 49.79 
HUR 018 168.6 78.4 78.9 28.11% 26.92% 56.36 57.66 
HUR 020 162 54.8 53.8 33.52% 31.38% 36.43 36.92 
HUR 023 165.1 62.2 62.3 35.05% 33.75% 40.4 41.3 
HUR 025 169.6 90.2 93.4 41.31% 46.84% 52.94 49.65 
HUR 027 161.6 100.9 101.4 46.48% 46.64% 54 54.1 
HUR 028 160 62.6 64.8 39.31% 33.23% 37.99 43.24 
HUR 030 161.8 60 60.4 30.67% 29.67% 41.6 42.45 
HUR 031 165 87.9 89.2 45.11% 46.02% 48.25 48.17 
HUR 032 168.6 95 95.4 34.21% 34.86% 62.5 62.16 
HUR 033 178 60.4 60.3 28.44% 30.13% 43.22 42.13 
HUR 034 175.5 88.5 88.7 39.40% 39.44% 53.63 53.73 
HUR 036 169 87.42 86.9 25.50% 26.00% 65.13 64.31 
HUR 038 164.9 63.5 63.5 21.10% 21.15% 50.1 50.07 
HUR 039 179.5 97 99.0 33.30% 32.19% 64.7 67.13 
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HUR 041 163.7 70.84 69.8 30.97% 30.52% 48.9 48.5 
HUR 047 179.6 92.64 95.0 30.92% 31.79% 64 64.8 
HUR 048 168.3 75 75.0 40.53% 38.93% 44.6 45.8 
HUR 049 165.1 87.09 88.8 49.67% 48.13% 43.83 46.08 
HUR 052 158 112.5 111.0 A1    
HUR 055 164.7 65.6 64.8 39.02% 37.19% 40 40.7 
HUR059 145.4 53.5 51.3 36.64% 37.76% 33.9 31.93 
HUR060 159.8 68.12 69.3 34.38% 37.05% 44.7 43.6 
HUR 062 173.4 79.12 79.3 29.44% 29.07% 55.83 56.22 
HUR 063 171.2 74.32 74.4 30.81% 28.36% 51.42 53.3 
HUR 065 178 97.27 99.3 30.42% 31.26% 67.68 68.26 
HUR 066 160.02 66.36 66.9 42.13% 41.85% 38.4 38.9 
HUR 068 178.2 77.7 78.1 25.62% 28.39% 57.79 55.9 
HUR 071 172.3 85.84 87.3 32.67% 33.30% 57.8 58.2 
HUR 073 176.1 104.2 105.6 35.99% 34.17% 66.7 69.52 
HUR 074 158.5 62.82 58.6 36.33% 33.11% 40 39.2 
HUR 075 172.1 88.56 85.6 28.48% 28.86% 63.34 60.9 
HUR 076 160.6 60.54 59.8 34.61% 35.54% 39.59 38.56 
HUR 077 156.4 67.96 65.8 36.79% 37.52% 42.96 41.1 
HUR 078 168.9 74.6 73.2 22.82% 21.20% 57.58 57.71 
HUR 079 176.5 92.53 97.9 30.15% 33.67% 64.63 64.94 
HUR 080 171 60.32 60.0 21.75% 21.83% 47.2 46.9 
HUR 081 143.7 57 58.9 32.28% 33.29% 38.6 39.29 
HUR 084 151.4 55.26 53.9 32.14% 31.95% 37.5 36.68 
HUR 085 190.4 115.8 115.5 29.71% 29.70% 81.4 81.2 
HUR 087 170.2 83.91 89.3 21.92% 24.95% 65.52 66.98 
HUR 091 154.9 63.95 65.4 40.73% 41.60% 37.9 38.21 
HUR 092 178.7 76.34 77.0 22.31% 23.13% 59.31 59.19 
HUR 093 162.1 77.84 77.4 43.65% 45.28% 43.86 42.35 
HUR 094 154.7 72.34 72.1 43.35% 45.40% 40.98 39.38 
HUR 097 155.6 66.9 70.4 36.41% 40.33% 42.54 42.01 
HUR 098 174.1 87.6 86.8 31.37% 34.06% 60.12 57.24 
HUR 099 178.5 88.8 89.6 27.82% 28.13% 64.1 64.4 
1 162.56 85.3 84.7 40.55% 29.74% 50.712 59.524 
2 170.18 65.5 67.1 22.06% 23.38% 51.051 51.38 
3 172.72 82.5 81.2 32.07% 30.23% 56.042 56.684 
4 175.26 88 89.8 35.93% 34.28% 56.386 58.997 
5 180.34 78 78.2 A2    
6 177.8 74.5 75.9 29.35% 29.27% 52.635 53.6715 
7 167.64 72.7 73.4 22.82% 22.32% 56.113 57.034 
9 175.26 83.4 82.9 29.84% 30.10% 58.512 57.926 
10 177.8 80.5 83.0 23.79% 25.31% 61.348 62.012 
11 177.8 96.5 97.2 34.81% 35.79% 62.911 62.416 
14 165.1 79.1 78.5 43.42% 42.90% 44.752 44.802 
16 154.94 69.4 67.9 43.47% 43.50% 39.229 38.381 
18 165.1 61 61.1 40.92% 38.71% 36.039 37.453 
20 154.94 65.6 65.7 41.78% 41.84% 38.194 38.199 
21 175.26 83 81.4 42.93% 39.77% 47.367 49.003 
22 149.86 66.3 64.1 43.08% 41.58% 37.738 37.435 
23 162.56 69.2 74.7 35.53% 38.66% 44.611 45.829 
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24 162.56 66.9 66.1 37.54% 35.86% 41.786 42.406 
                
SD 9.3 14.17 14.6 0.07 0.07 10.4 10.6 
Mean 167.1 77.20 77.5 0.34 0.34 50.5 50.8 
SEM 1.1 1.73 1.8 0.01 0.01 1.3 1.3 
        
A1 = Exceeded weight restrictions for accurate DXA analysis and was not scanned. 



























       
       
HUR 015 98 101 107 145 38 35.5% 
HUR 017 64 101 120 156 36 30.0% 
HUR 018 150 170 170 200 30 17.6% 
HUR 020 96 95 101 102 1 1.0% 
HUR 023 112 114 112 130 18 16.1% 
HUR 025 112 137 84 137 53 63.1% 
HUR 027 138 142 152 187 35 23.0% 
HUR 028 70 65 95 128 33 34.7% 
HUR 030 96 98 108 136 28 25.9% 
HUR 031 76 92 97 130 33 34.0% 
HUR 032 175 200 188 220 32 17.0% 
HUR 033 A3      
HUR 034 127 135 130 160 30 23.1% 
HUR 036 117 126 126 155 29 23.0% 
HUR 038 123 190 123 200 77 62.6% 
HUR 039 152 157 165 181 16 9.7% 
HUR 041 105 115 117 158 41 35.0% 
HUR 047 200 245 225 275 50 22.2% 
HUR 048 115 118 110 152 42 38.2% 
HUR 049 95 95 100 100 0 0.0% 
HUR 052 120 130 123 150 27 22.0% 
HUR 055 117 55 133 170 37 27.8% 
HUR059 61 46 65 64 -1 -1.5% 
HUR060 25 20 96 125 29 30.2% 
HUR 062 206 220 185 225 40 21.6% 
HUR 063 145 145 140 170 30 21.4% 
HUR 065 154 155 170 190 20 11.8% 
HUR 066 A4  85 103 18 21.2% 
HUR 068 114 140 158 185 27 17.1% 
HUR 071 136 140 175 190 15 8.6% 
HUR 073 166 160 130 170 40 30.8% 
HUR 074 120 125 125 141 16 12.8% 
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HUR 075 110 155 110 170 60 54.5% 
HUR 076 100 86 105 115 10 9.5% 
HUR 077 76 90 87 112 25 28.7% 
HUR 078 150 175 174 212 38 21.8% 
HUR 079 200 205 200 240 40 20.0% 
HUR 080 88 96 91 117 26 28.6% 
HUR 081 55 55 65 76 11 16.9% 
HUR 084 A5  80 95 15 18.8% 
HUR 085 191 200 175 205 30 17.1% 
HUR 087 220 246 245 285 40 16.3% 
HUR 091 A6  88 103 15 17.0% 
HUR 092 125 135 144 185 41 28.5% 
HUR 093 103 112 100 130 30 30.0% 
HUR 094 114 110 119 120 1 0.8% 
HUR 097 105 100 100 113 13 13.0% 
HUR 098 155 162 155 188 33 21.3% 
HUR 099 216 224 220 264 44 20.0% 
1 165 180 175 222 47 26.9% 
2 150 155 160 200 40 25.0% 
3 210 215 200 235 35 17.5% 
4 162 190 165 215 50 30.3% 
5 160 165 155 185 30 19.4% 
6 168 203 174 225 51 29.3% 
7 173 200 153 205 52 34.0% 
9 155 165 175 210 35 20.0% 
10 125 130 150 180 30 20.0% 
11 145 195 145 230 85 58.6% 
14 100 105 105 130 25 23.8% 
16 91 93 87 100 13 14.9% 
18 78 85 75 102 27 36.0% 
20 100 115 110 140 30 27.3% 
21 105 115 105 145 40 38.1% 
22 115 125 95 100 5 5.3% 
23 40 60 70 100 30 42.9% 
24 95 100 85 125 40 47.1% 
        
SD 43.44 50.45 41.67 50.13 16.29 0.13 
Mean 125.87 136.17 131.17 162.33 31.17 0.24 
SEM 5.47 6.36 5.13 6.17 2.01 0.02 
A3 = After training 1RM sheet was lost before data entry therefore none of her strength 
values were used. 
A4 = Invalid test at post-training for untrained leg.  Therefore, untrained strength values 
are not used. 
A5 = Previous injury on untrained knee therefore data for untrained strength not used. 
A6 = Invalid post-test due to pain/discomfort during test.  Her data for untrained strength 
not used. 
 

















 cubic cm cubic cm cubic cm cubic cm cubic cm 
      
HUR 015 1097.2 1100.2 1188.2 1281.6 90.4 
HUR 017 1300.0 1224.0 1321.7 1432.7 187.0 
HUR 018 1585.2 1578.2 1531.5 1641.0 116.6 
HUR 020 1062.7 1065.3 1029.1 1083.1 51.3 
HUR 023 680.0 696.0 1084.0 1172.0 72.0 
HUR 025 1183.8 1208.9 979.8 1139.7 134.7 
HUR 027 1490.0 1527.0 1442.0 1525.0 46.0 
HUR 028 A7     
HUR 030 1095.3 1094.9 1265.3 1303.1 38.1 
HUR 031 1024.8 1010.7 1203.4 1296.6 107.4 
HUR 032 1781.3 1788.6 1839.7 2011.7 164.7 
HUR 033 1315.0 1312.0 1245.0 1299.0 51 
HUR 034 1556.4 1548.2 1566.2 1705.3 147.3 
HUR 036 A8     
HUR 038 1428.0 1417.3 1347.4 1469.2 132.5 
HUR 039 1887.3 1882.1 1976.8 2053.5 81.9 
HUR 041 1601.0 1619.0 1802.0 1871.0 41.0 
HUR 047 2047.5 2095.2 2349.3 2605.1 208.1 
HUR 048 A9     
HUR 049 A10     
HUR 052 A11     
HUR 055 1139.2 1091.7 1286.1 1379.7 141.1 
HUR059 A12     
HUR060 255.3 258.5 1122.0 1283.0 157.8 
HUR 062 1650.7 1678.1 1731.3 1986.5 227.8 
HUR 063 1365.9 1435.8 1403.9 1571.4 97.5 
HUR 065 A13     
HUR 066 679.0 540.0 754.6 805.2 189.6 
HUR 068 1523.7 1476.9 1630.6 1692.0 108.2 
HUR 071 1602.1 1565.3 1652.9 1801.1 185.0 
HUR 073 1812.6 1772.5 1881.6 2039.1 197.6 
HUR 074 1156.4 1134.8 1211.7 1270.3 80.2 
HUR 075 1461.5 1422.5 1432.8 1550.9 157.1 
HUR 076 967.1 919.4 790.0 916.0 173.7 
HUR 077 975.6 965.9 1085.5 1138.1 62.3 
HUR 078 1599.3 1560.9 1638.0 1670.9 71.2 
HUR 079 1894.3 2035.0 1885.2 2036.9 11.0 
HUR 080 1174.8 1185.8 1185.8 1240.7 43.9 
HUR 081 903.8 906.2 789.5 854.7 62.8 
HUR 084 736.8 723.4 754.0 867.7 127.1 
HUR 085 2007.8 2069.1 1847.6 2016.8 108.0 
HUR 087 1952.0 1920.0 1820.0 2108.0 320.0 
HUR 091 907.9 894.3 900.9 982.0 94.7 
HUR 092 1644.5 1591.4 1625.4 1742.2 170.0 
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HUR 093 1030.0 1008.0 1042.0 1129.0 109.0 
HUR 094 1081.0 1037.1 1025.2 1126.5 145.1 
HUR 097 958.0 998.0 959.0 1043.0 44.0 
HUR 098 1601.0 1624.0 1650.0 1808.0 135.0 
HUR 099 1864.0 1845.0 1834.0 2120.0 305.0 
1 1768.0 1937.0 1755.3 2132.4 208.1 
2 1504.3 1564.9 1528.0 1691.6 103.0 
3 1785.4 1798.6 1815.4 2000.3 171.7 
4 1803.3 1894.0 1769.8 2055.0 194.5 
5 1188.0 1097.0 1718.6 1860.6 233.0 
6 1818.0 1834.0 1708.0 1948.1 224.1 
7 1683.0 1794.1 1615.0 1858.9 132.9 
9 1725.9 1749.5 1893.3 2040.9 124.0 
10 1662.9 1635.6 1696.2 1916.5 247.5 
11 1987.1 1974.0 1966.1 2085.6 132.5 
14 941.2 992.7 1217.2 1305.9 37.2 
16 941.2 992.7 1090.2 1245.7 104.0 
18 941.2 992.7 890.7 985.0 42.8 
20 1133.8 1150.1 1137.5 1257.9 104.1 
21 1223.6 1203.4 1258.6 1373.9 135.4 
22 1089.6 1127.4 935.7 1132.3 158.8 
23 870.3 948.1 920.0 1036.0 38.2 
24 1223.2 1226.6 1178.5 1295.7 113.8 
            
SD 402.14 416.73 379.43 420.8 67.4 
Mean 1356.17 1362.33 1403.42 1538.2 128.3 
SEM 51.92 53.80 48.98 54.3 8.7 
 
A7 – A13 = CT scan misalignment or poor clarity.  Therefore, scan analysis not reliable 
and data for muscle volume and quality not used.






APPENDIX G: LITERATURE REVIEW 
 
 The following review of literature provides background information relevant to 
the understanding of the influence of the IGF1 gene on ST adaptations in older adults.  
This review will focus on the following topics: 1) causes and consequences of sarcopenia, 
2) muscle strength declines with age, 3) muscle mass decline with age, 4) assessment of 
muscle mass and muscle quality, 5) mechanisms of sarcopenia, 6) strength training 
adaptations in the elderly, 7) genetic variability in skeletal muscle, 8) IGF-I physiology, 
and 9) IGF-I promoter polymorphism and the recommendations for future studies.  
            Causes and consequences of sarcopenia:  The term sarcopenia was coined by 
Rosenberg in 1989 (179).  It comes from the Greek words sarx (flesh) and penia (loss), 
literally meaning loss of flesh.  Sarcopenia refers to the loss of muscle mass with aging, 
which in turn affects function.  Skeletal muscle function, in this case, can be defined as 
the ability of muscle to do mechanical and/or chemical (metabolic) work.  The decline in 
work capacity of muscle is due to many factors, including a loss or detrimental change in 
the muscle’s total volume, strength, gene expression for synthesis of contractile proteins, 
metabolic characteristics, nervous system innervation and number and type of muscle 
fibers.  These changing characteristics of skeletal muscle can result in a decline in 
function with increasing age.  It has been reported from both cross-sectional and 
longitudinal studies that muscle function declines with advancing age (59,115,121,128).  
Although differences exist, the decline in muscle function is similar between men and 
women (115).  This functional decline in muscle leads to loss of independence, hip 
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fractures, morbidity and mortality (4,161,163).  Depending on the criteria used to classify 
sarcopenia, the number of people who are sarcopenic in the US is estimated to be about 9 
million (12).  With an aging society, this is estimated to expand significantly and become 
a major medical cost.  In the United States, census data report that 39 million Americans 
are over the age of 65.  Within six years, this will increase by more than 6 million (US 
census Bureau, 2000).  Consequently, health care costs will increase for the elderly.  In 
2001, projects spending totaled 103 billion dollars for nursing home stays, and by 2010, 
this will increase by 77% to 183 billion (Health Care financing administration, 2000).   
   Sarcopenia is believed to be a multifactorial process that occurs, to some degree, 
naturally as part of the aging process in humans, but with significant inter-individual 
variability.  The primary measures of loss of muscle function are muscle strength and 
mass (or volume).  The loss of both muscle strength and mass are a known consequence 
of aging.  Numerous cross-sectional and longitudinal studies have demonstrated  that 
muscle strength and mass decrease with aging (114,115,121,128).   
      Sarcopenia does occur ubiquitously yet with significant variability in humans.  
While the causes are yet to be fully elucidated, it appears that interventions to counteract 
sarcopenia hold much promise with ST being the most efficacious.  With an aging 
society, it becomes more important to address this disease process through a better 
understanding of its causes, prevalence, and treatment. 
 The first study to define sarcopenia in a large group was  in The New Mexico 
study reported by Baumgartner et al. (12).  In this study, sarcopenia was defined as 
having two SD below the mean appendicular muscle mass for healthy young adults.  
Baumgartner et al. (6) measured 883 elderly Hispanic, white men, and women 
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appendicular muscle mass by DXA.  The prevalence of sarcopenia ranged from 13 to 24 
% in persons 65 to 70 yr and was over 50% for those older than 80 yr.  Additionally, 
sarcopenic women had 3.6 times higher rates of disability and men had 4.1-fold higher 
rates compared with those with greater muscle mass.  Iannuzzi-Sucich et al. (45) used 
DXA to quantify appendicular skeletal muscle mass in 195 women aged 64-93 and 142 
men 64-92yr.  They defined sarcopenia as two SD below the muscle mass /height (m2) 
for young controls.  The overall prevalence of sarcopenia was 22.6% in women and 
26.8% in men and 31 and 45% respectively for women and men over age 80.  
The consequences of sarcopenia range from decreased functional capacity to increased 
mortality.    Several studies have reported an association between low muscle strength 
and increased  mortality rates (64,107,164).  It has been shown that corrected arm muscle 
area is a better predictor of long term mortality than BMI which is an often used predictor 
of mortality in older adults (130).  Additionally, Tellado et al. (98) demonstrated that 
body cell mass was the best predictor of mortality in an intensive care unit independent of 
diagnosis.  In a recent report from the BLSA, Metter et al. (69) reported  that hand grip 
strength was a predictor of mortality as was the change in hand grip strength, independent 
of physical activity or muscle mass. 
Muscle volume and strength reach a peak between 40 and 50 yrs of age and 
remain relatively constant until the fifties.  Beginning in the sixties muscle strength will 
begin to decline at approximately 12 - 14% per decade and muscle mass will decline at ~ 
6% per decade (121).  This amounts to a loss of muscle function of ~ 40% by the eighth 
decade of life and often leads to disability and morbidity and possibly even mortality 
(129,131).  With an aging population, this is becoming a greater public health concern. 
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 Muscle Strength decline with age:  The age related losses in muscle strength are  
related to changes in neural drive, altered muscle pennation angle, increases in connective 
tissue, loss of type II fibers, and decreased expression of MHC proteins (6,97,104,114).  .  
Cross-sectional as well as longitudinal studies have consistently demonstrated a 
significant loss of muscle strength beginning in the 50s or 60s for men, and slightly 
earlier in women (115,121) .  The average reported age-related decrease in strength is 20-
40% when young subjects are compared to those in their 70s or 80s  (106,228,229).  Men 
have a greater absolute loss than women, yet begin with a greater amount and thus will 
retain a greater absolute amount of muscle strength than women even after aging.  
Starting with a lower absolute value combined with the fact that they live longer, women 
are believed to be more susceptible to sarcopenia and live a longer time in infirmity than 
men (108).     
Investigators have concluded that concentric strength tends to peak in the  30s, 
then plateaus until ~50 yr of age and then declines at a rate of ~10-15% per decade 
(60,106,116).  Indeed, this decrement is at least partially due to a decline in force 
production by muscle fibers.  Single muscle fibers from elderly humans have been 
studied and compared to younger adults cross-sectionally.  For example, Frontera et al. 
reported older men (~75 yr) having a 35% reduction in force generation in type IIa fibers 
than younger men (~35 yr) (61).  In another cross-sectional study, Trappe et al. (208), 
reported older women having 25-40% less power in single fibers when compared to 
young women, old men, and young men .  Older women also demonstrated a reduced 
force production in single fibers  (208) .  Thus, it seems that the reduction in whole 
muscle strength is at least partially due to decrease in force generating potential of single 
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muscle fibers.  This assumes that all motor units in the muscle are being fully activated.  
Yet, if the elderly cannot maximally activate existing musculature then force production 
of muscle fibers may not be much of a limiting factor.  It does appear that older 
individuals can fully and maximally contract their remaining musculature as the twitch 
interpolation technique has demonstrated full or near full contraction of muscle in the 
elderly (29,82,101).  Although some studies have shown less than full activation in older 
adults and as low as 69% (75,196).  Additionally, ST did not seem to increase maximal 
musculature activation in those who could not fully activate their muscles (75).  Yet a 
recent report suggests that with practice  elderly men can fully activate their elbow 
flexors and extensors if a deficit was present (86).  Previous studies have not allowed a 
skill learning or practice period for measured strength tasks.  Thus, drawing evidence 
from the numerous aforementioned studies of varying design, it would seem that there is 
a significant decline in muscular strength with advancing age.  Yet individuals do not 
experience this decline in strength at identical rates.  For example, Kallman et al. in a 
cross-sectional analysis of 847 subjects 20 to 100 yr, reported grip strength peaked in 
fourth decade and declined in curvilinear fashion thereafter, so that by the ninth decade 
strength had declined 37%.  Their longitudinal analysis, however, showed that 15% of the 
subjects aged 60 yr and over exhibited no strength decline during an average 9-yr follow-
up, suggesting significant interindividual variability in the loss of strength.   
Muscle mass decline with age:  The loss of muscle mass with age is highly 
correlated with and is likely a contributing factor to the loss of muscle strength that 
occurs with age (60,167,229).  Depending on the measurement technique used, muscle 
mass has been reported to decline with age at a slower rate than muscle strength (6,125).  
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Although various measurement techniques have been used to estimate losses in muscle 
mass with age (ultra-sound, computed tomography scanning (CT), magnetic resonance 
imaging (MRI), creatinine excretion, 40K counting, dual-energy x-ray absorptiometry 
(DXA), and hydrodensitometry), little or no information is available from direct 
measurement of muscle mass.   Nevertheless, based on estimations, it seems that skeletal 
muscle mass declines approximately 40% from the 30s  to the 90s , with a 10% decline 
occurring from the 30s  to the 60s  (87,102,114,125,149,228,229).  Using ultrasound, 
Young et al. reported a 25-35% decrease in quadricep muscle cross-sectional area (CSA) 
in old men and women when compared with controls (228,229).  Similar reports of a 
decline in muscle mass come from CT scans of older and younger men (102,149). Lexell 
et al. (114) utilized whole muscle post-mortem analysis to measure size of whole muscle, 
number of fibers, and fiber size to quantify total changes in aging muscle.  He compared 
CT cross-section of whole muscle post-mortem reporting a 40% decline in CSA from the 
30s  to the 70s  (114).   
Assessment of muscle mass  For a faster, non-invasive, more economically 
efficient measurement of muscle mass, dual-energy absorptiometry (DXA) has been 
employed in body composition studies.  However, the technology relies on the 
assumption of x-ray attenuation through bodily tissues remaining constant from person to 
person and throughout aging.  It has been reported that DXA tends to overestimate the 
amount of lean tissue in the elderly because DXA cannot distinguish between water and 
other lean tissues (155).  Thus, DXA may underestimate the loss in FFM.  Many of the 
aforementioned studies examined only men and only one or two muscle groups.  A few 
studies have overcome these methodological shortcomings (65,87,121).  Lynch et al. 
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(109)  assessed 502 men and women from the BLSA utilizing DXA scans of the upper 
and lower body(121).  They reported an 18% loss of leg muscle mass in men and a 15% 
loss in women from the 40s to the 70s.  Arm muscle mass showed a slightly greater 
decline (21%) with age but was similar between men and women (121).  Examining 148 
women and 139 men ages 20-90, Gallagher et al. (65) reported a total appendicular 
skeletal muscle mass decline of approximately 15% for men and 11% for women after 
adjusting for height, weight, and age. Utilizing MRI, Janssen et al.  (87)studied 268 men 
and 200 women analyzing whole body skeletal muscle mass ages 18-88.  They  reported 
an approximate 27% decline in skeletal muscle mass in men and slightly less decline in 
women but women began with almost 40% less muscle mass (87).  Again, it is possible 
that DXA is underestimating the loss of FFM with increasing age.  Additionally, cross-
sectional studies likely underestimate the loss of FFM because the elderly pool of 
subjects for these studies are on average, likely to be healthier than their peers who did 
not survive to the time of the study.  Thus, only the healthiest individuals may survive to 
have all measurements completed.  Therefore, it seems that muscle mass is lost at a rate 
of at least 6% per decade after the 40’s for women and 60’s for men.   However, it should 
be noted that there is significant variability in the loss of muscle mass with age (121,128). 
Muscle Quality: The quality of lean body mass declines with age (51).  As 
measured by 40K counting, body cell mass declines faster with age, than intercellular 
connective tissue and water.  Thus, a pound of lean mass from an elderly person contains 
less intracellular tissue and more extracellular tissue.  In young men (20-25), cell mass 
represents 59% of lean body mass while in old men (80-89) cell mass is only 46% of lean 
mass (44).  An 18 year longitudinal study of 564 men and 61 females reported that body 
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cell mass, driven by muscle mass, declines linearly with aging (55).  Measures of muscle 
quality (MQ) sometimes referred to as specific tension or strength per unit of muscle 
volume, takes into account an estimate of skeletal muscle in contrast to lean body mass or 
fat-free mass.  Muscle quality depends on accurate measures of force production and 
muscle size, full central activation of muscle, ensuring that only the muscles of interest 
participated in force production, and effects of pain or other neural inhibitory factors are 
accounted for (38).  Early studies were conflicting, i.e. Young et al. (228) found no 
difference in force production/cross sectional area (CSA) of the knee extensors of older 
women compared to controls (228).  Yet other reports have found a loss of MQ occurring 
with advancing age (60,167,229).  Muscle quality has been shown to decline both at the 
whole muscle level (121) and at the single muscle cell level (59).  Lynch et al. (121)  
reported  a decline in MQ in the leg musculature and that arm muscle quality decreased to 
a similar extent, but the decline in arm MQ was more pronounced in women.  
Additionally, Frontera et al. (61) examined single muscle fibers in young and older men 
and women in a cross-sectional design and reported a decline in muscle fiber quality in 
men.  Thus, it seems that MQ declines with age, but the magnitude of decline depends on 
gender and individual responses. 
Mechanisms for the decline in muscle size and function with age:  No single 
cause has been identified that explains the decline of muscle size or function with age.   
Yet, many interrelated factors have been identified that likely contribute to sarcopenia .  
Some of major factors seem to be a loss of alpha motor neurons, declines in testosterone 
and estrogen, growth hormone, IGF-1,  protein synthesis, changes in myosin heavy chain 
(MHC) gene expression) and an elevation in catabolic stimuli such as TNF alpha. 
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 The total number of central nervous system and muscle neurons is known to 
decrease with age (19,174).  Furthermore, this loss of muscle neurons seems to be 
predominantly of the fast motor unit (36,40).  These losses are  related to the loss in 
muscle strength that occurs with age (39,40).  The preferential loss of fast fibers is 
thought to cause reinervation by slow motor units thus transforming them to the slow 
myosin type (40).  This would explain the increased motor unit size that is observed with 
advancing age.  In total, this translates to a decreased number of the higher force and 
velocity producing fibers.  This could result in reduced force and or power production by 
the muscle of interest due to the loss of the more powerful muscle fibers.  Yet, Urbanchek 
et al. (107)  reported that only 11% of the decrease in muscle force production is  
attributable to denervated fibers (213).  Furthermore, some recent evidence suggests that 
the loss of motor neurons that occurs with age is not as much as was once thought (133). 
 The turnover of proteins is a constant metabolic process within the body.  High 
protein turnover helps maintain muscle quality by replacing damaged or deformed 
proteins.  To maintain protein balance, synthesis must be equal to the degradation rates.  
In normal healthy humans, this is the case and there is a no net change in whole body 
protein.  Muscle contractile and mitochondrial protein synthesis rates are reduced with 
advancing age (7,139,175,176).  A cross-sectional study by Welle et al. (219) measured 
total and fractional protein synthesis in young men (21-31) and older men (62-81).  They 
demonstrated that the fractional rate of myofibrillar protein synthesis was 28% slower in 
the older group compared to younger.  Total myofibrillar protein synthesis, estimated as 
total myofibrillar mass (from creatinine excretion) times the fractional synthesis rate, was 
44% slower in the older group.  Whole body protein synthesis was lower in the older 
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group even after adjusting for total FFM (219).  In contrast, a study by Morais et al. (72) 
reported that after correction for FFM, whole body protein turnover was not decreased in 
the elderly.  Balagopal et al. (2), reported that whole body muscle protein synthesis 
declined by about 50% when young were compared to the elderly but whole body non-
muscle protein synthesis did not change.  This was primarily due to the decrease in 
synthesis rate of myosin heavy chain proteins.  In another study by Balagopal et al. (4), 
mixed muscle protein synthesis and gene transcript levels of (myosin heavy chain) MHC-
IIa and MHC-IIx were shown to decrease with age, whereas, MHC-I did not differ based 
on age.  Consequently, ST increased the levels of MHC-I, but did not change the MHC-
IIa and IIx in the same subjects.  This finding suggests that protein synthesis may not be 
different with age in response to ST, but MHC expression levels do differ with age.  In a 
ST study of frail elders, Yarasheski et al. (226) reported that despite a large increase in 
the fractional rate of protein synthesis in the exercise group, the rate of whole body 
protein synthesis only tended (not statistically significant)to increase after resistance 
training.  Whole body proteolysis rate and protein synthesis rate were unchanged in the 
frail elders after 3 months of ST.  The exercise did stimulate the in-vivo rate of vastus 
lateralis (mixed) muscle protein synthesis.  It was concluded that skeletal muscle 
contractile proteins in 76- to 92-yr-old physically frail elders retain the ability to increase 
the rate of fractional muscle protein synthesis in response to progressive  resistance 
training (226).  The non-significant finding of whole body protein synthesis change with 
ST is not surprising given that skeletal muscle only accounts for ~25% of total body 
protein synthesis.  Therefore, the increases seen in muscle protein synthesis are not likely 
to be detected at the whole body level.   
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Hasten et al. (77), examining a group of older men and women, reported the older 
adults having a lower MHC and mixed vastus lateralis muscle protein synthesis rate than 
23-32 yr olds.  Baseline actin protein synthesis rates were similar between the two age 
groups. After a ST program, it was reported that as a result of their lower whole body 
skeletal muscle mass, 78-84 yr olds had lower absolute rates (g protein synthesized/day) 
of MHC, mixed, and actin protein synthesis than 23-32 yr olds.  Exercise increased mixed 
muscle and MHC protein synthesis rates in both age groups.  Thus, it seems that 
contractile protein anabolic actions in response to acute resistance exercise are not 
compromised by advanced age.  And in response to ST, rates of whole body proteolysis, 
protein synthesis, and leucine oxidation, when expressed in kilograms of FFM, are not 
different between younger and older subjects (77).  The preceding studies suggest that a 
reduction in muscle protein synthesis is likely a contributing factor to sarcopenia, but the 
decline is reversed by a ST intervention. 
The Role of Hormones:  Several hormones play a role in muscle protein 
synthesis, satellite cell activation, and overall muscle growth.  Testosterone (T), GH, and 
IGF-1 are all known to have an anabolic effect on skeletal muscle.  However, all of these 
exhibit a decline with age (10,74) .  Administration of GH has been shown to increase 
lean muscle mass and protein synthesis in humans. (63,185).  Yet, although GH may 
increase whole body protein synthesis it seems to have no effect on skeletal muscle 
strength (227).  Serum T levels decline gradually by the fourth decade of life (74).  This 
decline is even more dramatic for unbound testosterone partly due to the increased sex 
hormone-binding globulin concentrations being higher in older men  and has been 
associated with a decreased FFM (183).    Administration of gonadotropin-releasing 
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hormone antagonist causes a decrease in FFM, muscle strength, and muscle protein 
synthesis (122).  Epidemiological studies have lent further support to the hypothesis of 
decreasing muscle mass and strength with decreasing T levels (13,151,183).  In a study of 
hypogonadal men, T increased FFM but not strength after 3 years of administration 
(193).  Some studies have shown that T will increase some measures of strength, 
although it has not been shown to increase knee extension strength, which is known to be 
associated with daily function in the elderly.  Only two studies to date have used older 
men not considered hypogonadal in a double blind randomized placebo trial (22,95).  
Snyder et al. (194) found an increase in FFM, but no change in leg strength, whereas, 
Ferrando et al. (47) found that some measures of strength increased.  Yet the increases in 
strength were less than typically found in a short-term ST intervention.  Some of the 
possible side effects of T therapy include increased prostate size, increased hematocrit, 
and altered lipoprotein levels.  Thus, its safety is still a concern. 
 T administration has been shown to increase IGF-1 muscle expression levels (47) 
and is a possible mechanism by which T may cause muscle hypertrophy.  IGF-1 levels 
decline with advancing age and are thought to be causally related to the decline in muscle 
function observed with age (69,71).  The somatomedin hypothesis suggests that 
circulating GH is causes expression and secretion of IGF-I by the liver.  According to this 
theory, the liver is the primary source of circulating IGF-I and is under the direct control 
of GH.  GH and circulating IGF-1 levels both decline with age at a similar rate.  In young 
adults who were GH deficient, GH therapy increased circulating GH and IGF-I levels and 
increased muscle mass (79).  Additionally it is known that IGF-I is expressed by muscle 
and acts in an autocrine/paracrine fashion to simulate muscle protein synthesis (71).  
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Consequently, a study that administered GH in older men did increase plasma IGF-I 
concentrations but did not increase the mRNA for IGF-1 in muscle (218). 
Strength training adaptations in elderly:  Due to the prevalence in the 
population, total health care costs, and detrimental physical consequences of sarcopenia, 
it would be beneficial from an economic and public health perspective to find a safe and 
effective method to increase muscle strength and mass in the elderly.  As noted 
previously, hormone supplementation in the form of HGH has not proved effective and 
has been shown to be unsafe (15).  In addition, the safety and efficacy of T is not yet 
clear.  However, strength training (ST) in the elderly has been shown to be both safe 
(81,153) and effective in increasing muscle strength and mass in as little as 8 weeks (50).  
Indeed, several studies have demonstrated the efficacy of ST to increase muscle mass and 
strength in men and women age 50 – 98 (17,49,50,62,83).  Additionally, the muscle 
adaptations due to ST have been shown to have a positive effect on functional ability in 
the elderly (18,186).   
 Muscle strength increases ~25 to 45% in response to ST in the elderly 
(49,84,95,109,210).  At least one study has shown that muscle strength responds to the 
stimulus of ST up to the age of 98 yrs (50).  Most studies would suggest that there is little 
or no age effect in the muscle strength response to ST.  However, Lemmer et al., reported 
slightly but significantly greater strength gains (34%) in 20-30 year old men and women 
when compared to 65-75 old men and women (28%) (109).  Yet, there was no age 
difference in the response of muscle volume to the same ST program (83).  These data 
suggest that in response to ST, elderly muscle adapts similarly as younger muscle in 
response to progressive muscle overload (ST).     
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 Depending on the method of measurement, intensity of the program, and possibly 
age and sex of the participants, total body muscle mass generally increases, but with a 
range from no significant change to a 41% increase (22,62).  In a 12 week ST program of 
men and women 56-80 yrs, Campbell et al. (22)  reported a small increase in FFM but no 
change in body cell mass as estimated by hydrostatic weighing and K-40 counting (22).  
Yet another study utilizing similar methods has reported increases in total body lean 
tissue of 10% (21).  In the latter study, measures of creatinine excretion were used in 
addition to hydrostatic weighing, potentially explaining the greater increase in lean tissue 
observed in the latter study.  It seems that creatinine excretion yields the highest 
measurement for changes in lean tissue due to ST in the elderly of 9 - 41% (21,62,142).  
The difference in measurement techniques is larger than would be expected; yet, each of 
the measurement techniques relies on the quantification of different factors.  Moreover, 
each has specific assumptions for estimating lean tissue mass.  Furthermore, it is likely 
that whole body lean tissue probably does not change much in a short- term study based 
on the findings of the change in actual muscle volume. 
 Change in muscle volume or cross-sectional area allows the measurement of the 
specific muscle being stimulated and allows the differentiation of muscle bone and fat.  
Muscle volume or cross-sectional area is typically measured by computed tomography or 
magnetic resonance imaging.  Several studies have shown the effects of ST in the elderly 
to cause an increase of ~8% while the range is 3 – 23% (50,62,68,173).  Frontera et al. 
(31) reported one of the first studies to use imagining techniques (CT) in response to a ST 
program.  They observed a 9% increase in the CSA of the knee extensors in a group of 60 
-72 yr old men who underwent a 12 week ST program. .  Two studies have used subjects 
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in their 90’s and showed increases of 3% and 10% respectively (51,76).  Some studies 
have used muscle volume as opposed to CSA to examine the changes in muscle size 
(83,96,206).  These studies have shown similar or greater increases in muscle due to ST.  
Indeed it has been suggested that muscle volume is a much more accurate method of 
reporting changes in muscle size due to ST (207).   
 Yet, even with the accuracy of the measurement of muscle size by medical 
imaging techniques, it does not measure changes at the myofiber level.  At the single 
muscle fiber level, it appears that changes due to ST are greater when expressed in % 
increases than when measured by imaging at the level of a whole muscle group.  The 
increases in fiber size are typically at least 10%, but often more than 30%.  This is not 
completely surprising because MRI and CT assessment of whole muscle groups are also 
measuring connective tissue and other tissues, which are not likely to change much as a 
result of training.  The increase in fiber size is seen in both type I and type II fibers 
(17,21,49,62,113).  Additionally, training studies have been conducted in older adults that 
examined functional changes at the fiber level.  Trappe et al. (211)  examined men before 
and after 12 weeks of ST examining single muscle fibers via muscle biopsy.  They found 
an increase in fiber area of 20% in type I fibers and 13% in type II fibers.  Force 
increased by 35% in type II fibers and by 20% in type I fibers.  Shortening velocity 
increased 75% in MHC I and 45% in MHC IIa.  Additionally power increased 56% in 
both fiber types combined (211).  In a similar study of older women (74 ± 2 yr), 
following 12 weeks of ST, fiber diameter increased by 24% in type I fibers and made no 
change in IIa fibers.  Force increased by 33% in type I and 14% in type II fibers.  
Shortening velocity was unaltered in both fiber types following the training, yet power 
 - 78 - 
increased 50% in type I and 25% in type II fibers (209).  It is concluded from these 
studies that, although sex differences may exist, muscle strength measured at the whole 
muscle level and single muscle fiber level increase in response to ST in the elderly. 
Effects of ST on muscle quality: The loss of muscle strength with age is thought 
to derive from the loss in muscle mass (91,106), neuromuscular function (91,106), and 
contractile properties of muscle(59,208).  Additionally, changes in connective tissue 
(149) and the decrease in muscle fiber pennation angle (104) are associated with aging 
and the loss of strength.  Recent studies have demonstrated an increase in MQ following 
ST (47,101).  In response to a 9 week ST program, Tracy et al. (101) reported a 14 and 
16% increase in MQ (quantified by 1-RM and muscle volume) for men and women 
respectively (206).  Ivey et al. (47) examined the training and detraining effects on MQ 
with age and gender comparisons.  They found that young and older men and women 
increased MQ, but after a period of detraining, the older women were the only group to 
decrease MQ.  This is of specific concern because older women begin with lower 
strength and MQ and live longer than men, making them more susceptible to functional 
decline and dependence later in life.  Furthermore, older women suffer greater disabilities 
than older men (94).  Studies at the single fiber level suggest that men may increase 
muscle quality while women do not.  Yet, Ivey et al. (47) showed just the opposite in the 
young women. 
Genetic variation in muscle at baseline and in response to training:  Several 
interventions have been proposed for the prevention and treatment of sarcopenia, but it 
appears that ST is the most effective with the least side effects (15,81).  Large increases 
in strength and muscle mass can result in a relatively short time with ST, but these 
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changes are highly variable (83).  For example, in a ST study from our lab, 65-75 year 
old men and women varied in their strength increases from 5 – 59% (5 – 86 lbs.) and 
from  1 – 20% (19 – 344 cubic cm) in increases in MV (83,109).  The subjects in the 
aforementioned study were of similar age, health history, and past exercise training 
status.  Additionally these subjects underwent training programs of identical time, 
intensity and, type.  With the controls of this study, it would be expected that individuals 
would have similar responses.  This variation in muscle adaptation in a well-controlled 
study suggests a genetic determinant.  Further support for a genetic association comes 
from twin studies showing > 50% of the variance in baseline strength and lean body mass 
is attributed to heredity (20,57,143,190).  Adaptation of muscle to ST has also been 
shown to be highly heritable (200,201).  
The estimation of heritability of a specific trait is commonly estimated by the 
study of monozygotic and dizygotic twins.  The most common analysis is the 
measurement of a phenotype between and among sets of monozygotic and dizygotic 
twins.  Monozygotic twins share identical genetics or 100% of their alleles while 
dizygotic twins share ~50% of their alleles.  In theory, a trait that has a perfect correlation 
of 1.00 between sets of monozygotic twins and a correlation of .50 between dizygotic 
twins would suggest that the trait is purely under genetic control.  However, many 
additional factors can affect this estimate among these are similar environment, additive 
genetic and dominant genetic effects, and unique environments.  One approach to account 
for each factors influence is through a biometric path-analysis, which attempts to analyze 
all possible contributing factors to the measured phenotype of interest.  This method 
allows distinction between narrow and broad sense heritability. 
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Narrow sense heritability is defined as the ratio of a trait’s additive variance to it’s 
total variance and is a measure of the predictability of offspring trait values which are  
based on parental trait values (1).  Because the additive variance does not always give an 
adequate assessment of the influence of genetics on a trait, it is important to consider the 
dominance variance and, hence, the broad sense heritability of traits.  Unlike additive 
variance, which measures the variance due to mean effects of single alleles, the 
dominance variance of a trait measures the variance due to the interaction effect of the 
two alleles that constitute the genotype at a locus, summed over the genome (1).  The 
importance of these factors on traits such as fat free mass is demonstrated in the study of 
a founder population, which originated in the Tyrolean Alps and currently resides in 
South Dakota on communal farms.  With the use of family pedigrees and path analysis, it 
was estimated that the trait of fat free mass has a narrow heritability of .45 and a broad 
heritability of .76, suggesting a role for both additive and dominant effects on this trait.    
This study demonstrates the need for analysis of both broad and narrow sense heritability 
in that one third of the heritability estimate would have been overlooked if not for the 
estimation of the broad heritability.  It is interesting to note that systolic blood pressure in 
this population had a narrow heritability close to zero while the broad heritability was .45 
(1).  Again, this emphasizes the importance of analyzing both the broad and narrow sense 
heritability. 
In a study by Thomis et al., (203) path-analysis models were used to determine 
the relative genetic and environmental contribution to the observed variation in maximal 
isometric and dynamic strength and muscle cross-sectional area in twins.  Their approach 
used linear models to represent hypotheses about causal paths (latent to observed 
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variables) and correlational paths (between the latent variables) to explain the observed 
variation in a trait based on observed phenotypes and known relations in genetically 
related individuals (141,203).  In this model, the latent causal factors can be genetic, with 
additive (A) or dominance (D) gene action, environmental causes can be shared by twins 
or family members that are reared in the same family (C, from common environment) 
and non-shared or specific environmental factors (E, includes also random measurement 
error) (141,203).  Path-analysis examines variations of the ACDE model to determine the 
most parsimonious model fitting the data.  In some cases, it may be determined that any 
one of factors will be excluded from the model for a particular trait.  For example, it was 
found that the variation for most strength and anthropometric measurements was best 
explained by a model with additive genetic and unique environmental factors only (no 
dominant or common environmental factors found to be significant in the model) (203).  
The genetic determination of maximal static strength varied between 70 – 78% depending 
on the angle of measurement, with unique environmental factors accounting for the 
remaining variation (22 – 30%) of maximal torque at these angles.  In contrast, adipose 
tissue measured by CT scanning had 48% of variability explained by common 
environmental effects, 40% by additive genetic effects, 12% by unique environmental 
effects, and environmental factors, unique to the individual as well as measurement errors 
contributed for the rest (5-14%) (203). 
Another study by Thomis et al., utilizing twins found that 66-78% of the variance 
in maximal muscle torque was explained by additive genetic factors, whereas unique 
environmental factors accounted for 22-34% of the variance (202).  In this study, 
monozygotic and dizygotic correlations suggested the contribution of nonadditive genetic 
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factors contributing to the total variance.  However, nonadditive factors were not 
significant in the model and therefore dropped from the analysis.  Similar results were 
reported in the only study that has examined the contribution of genetic factors on the 
response to strength training.  This study utilized twins with the path-analysis model and 
again concluded that baseline strength was ~70% due to additive genetic factors and 30% 
due to environmental factors (E).  Additionally, it was found that training-specific genetic 
factors were significant for the post-training measures and were estimated to explain 
about 20% of the variation in achieved 1RM and isometric strength measures.  Thus, it 
seems that different genes may control the response to RT in comparison to those that 
control baseline measures of muscle strength. 
Only two studies could be found that examined the effects of a specific candidate 
gene polymorphism on strength or muscle mass at baseline or in response to training 
(56,83).  Folland et al., reported a significant relationship between the ACE genotype and 
strength response to ST (56).  Myostatin is another candidate gene that has been 
identified as potentially having an effect on muscle response to RT (83).  Although the 
effect of myostatin polymorphisms in humans have not been conclusive (48).  Due to 
their known association with muscle hypertrophy, genes coding for proteins that regulate 
or are regulated by growth hormone or its mediators (IGF1 and II) are prime candidate 
genes for influencing muscle mass and strength.  Indeed, a report from the Heritage 
Family Study revealed an association between an IGF1 gene marker and FFM (25).  
Furthermore, this same marker has been shown to be linked and associated with the 
change in FFM due to exercise training (25,198).  However, the training modality used in 
the Heritage study (25) was one that is not commonly associated with significant 
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increases in FFM. Nevertheless, an area near the IGF1 gene locus was implicated in these 
studies for influencing FFM both at baseline and in response to training, thus making it a 
strong candidate gene for muscle mass, as well as strength.    
IGF1:  The IGF1 gene consists of 88,066 base pairs and is located on human 
chromosome 12 (12q22-q24.1).  The gene contains two known promoters, six exons and 
5 introns.  Depending on tissue of origin and transcriptional splicing the mRNA typically 
contain 153 amino acids and is eventually translated into a 70 amino acid protein with 
three disulfide bridges.  The mRNA can produce at least three different transcripts, two of 
which are expressed in skeletal muscle. 
The somatomedin hypothesis came from early experiments trying to understand 
somatic growth caused by the pituitary gland.  These experiments used an assay that 
measured incorporation of  35SO4 into chondroitin sulfate from cartilage (184) as a 
measurement of somatic bone growth.  Hypophysectomy of rats reduced incorporation of 
35SO4  into chondroitin sulfate of cartilage (136), while exogenous injections of pituitary 
extracts and bovine GH restored 35SO4  this incorporation (184).  Yet, when GH was 
placed directly on costal cartilage slices in vitro, only a minimal effect of incorporation 
was observed (33).  Thereby suggesting that GH may be modulating the levels of another 
hormone in the circulation, which mediated the growth effects.  Further experiments 
helped to solidify the hypothesis which came to be known as “the somatomedin 
hypothesis” (32).  This hypothesis suggests that GH works indirectly by way of 
mediation factors to cause somatic growth. 
 Insulin-like growth factor I was eventually purified from rat serum and shown to 
be the somoatomedic substance regulated by GH (170).  It was termed “insulin-like” 
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because of its ability to stimulate glucose uptake into fat and muscle cells (160).  
Additionally IGF-I shares ~50% amino acid identity with insulin (170).  The primary 
structural difference between insulin and IGF-I is that IGF-I retains the C chain that is 
cleaved from proinsulin during post-transcriptional processing (170).  Upon the discovery 
of IGF-I, the hypothesis was further refined to suggest that GH secreted by the pituitary 
would act on the liver as its target organ, where IGF-I would be secreted to act on bodily 
tissues causing growth and provide feedback to the pituitary to control the level of GH 
secretion. 
 The first indication that the somatomedin hypothesis was incomplete was when 
D’Ecrole et al. in 1980, discovered that explants of fetal mouse tissue maintained in 
serum-free media showed higher levels of IGF-I in the culture medium as compared with 
extracts of the tissues themselves: liver, intestine, heart, brain, kidney, and lung (31).  
Additional studies supported the finding of various tissues expressing IGF-I (172).  It was 
further demonstrated that IGF-I production by various tissues of the body could be 
affected by and also act independent of GH plasma levels (119,120).  These tissues 
included lung, kidneys, heart, and skeletal muscle (119,120).  However, the direct effect 
of GH on non-hepatic tissues was still in question and it was subsequently shown that GH 
could affect tissues via stimulating local production of IGF-I or act directly on tissues to 
cause growth (67).  The latter process occurred without a mediating factor but was not as 
dramatic as when IGF-I was involved in the process. 
 IGF-I action:  IGF-I displays numerous diverse functions during both embryonic 
development and postnatally.  Indeed, mice carrying null mutations in the IGF-1 gene are 
born small and grow very poorly postnatally (5,154).  Naturally occurring mutations in 
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the IGF-1 gene are rare.  Only a single patient, with both intrauterine and postnatal 
growth retardation has been found who had a deletion of the IGF1 gene (222).  The 
complete physiological functions of IGF-I are beyond the scope of this review.  
Therefore, a brief background of IGF-I action will be given with specific emphasis on 
skeletal muscle. 
 As mentioned previously IGF-I exerts some of its influence as an endocrine 
hormone circulating in the blood stream until reaching a target tissue.  Unlike insulin, 
IGF-I in the circulation is bound to one of six known IGF binding proteins (90).  These 
binding proteins act as carriers of IGF-I to transport it out of circulation and prolong the 
half-life by protecting it from proteolytic degradation.  In addition to their role in 
circulation, binding proteins are often expressed by target tissues where they act to 
regulate IGF-I function further.  Binding proteins have been shown to augment and 
attenuate IGF-I action depending on the target tissue (166). 
 Once released from the binding protein, IGF-I can bind to the insulin or IGF-I 
receptor though it has much greater affinity for the IGF-I receptor.  It is likely that IGF-I 
actions vary depending on the receptor to which it attaches.  The insulin and IGF-I 
receptor share certain regions, with homology up to ~85%, including the tyrosine kinase 
domain (212).   The IGF-I receptor is a heterotetrameric transmembrane protein 
consisting of 2 identical extracellular alpha subunits containing cysteine-rich IGF-I 
binding sites and 2, primarily intracellular, beta subunits containing ATP-binding sites 
and a cluster of three tyrosines, which upon IGF binding undergo rapid phosphorylation 
and are required for activation of tyrosine kinase activity (110,197).  Ligand binding 
results in a conformational change leading to autophosphorylation of critical tyrosine 
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residues that activate cytoplasmic proteins containing SH2 (src homology 2) domains.  
However, unlike other receptor tyrosine kinases, the IGF receptor interacts with 
intermediate signaling proteins, insulin receptor substrate (IRS-1) and src homology 
containing protein (Shc).  Thus giving this receptor more complexity and versatility to 
modulate cellular transcription and translation (54). 
 The activation of IRS-1 by IGF-I binding to the IGF-I receptor results in the 
activation of phosphatidylinositol 3-kinase (PI 3-K).  In mammalian muscle, the PI 3-K 
pathway has been shown to mediate skeletal muscle hypertrophy.  In transgenic muscle, a 
mutant form of the Ras proto-oncogene that was only competent to stimulate the PI 3-K 
pathway, stimulated the PI 3-K pathway and caused skeletal muscle hypertrophy directly 
and blocked denervation-induced atrophy (135).  
The IGF-I receptor has been shown to mediate amino acid uptake in muscle as 
well as decrease protein degradation, stimulate proliferation and differentiation of 
myocytes and increase DNA synthesis in muscle satellite cells (41,45,231).  Mice lacking 
the IGF-I receptor die immediately after birth of respiratory failure and severe growth 
deficiency (45% of normal) (117).  Transgenic studies have concluded that IGF-I 
mediates its proliferative and differentiative effects via the IGF-I receptor (157).  The 
IGF-I receptor plays a role in the regulation of transcription of a number of genes 
encoding proteins involved in growth and metabolism.  Several of the immediate early 
genes, c-fos and c-jun are associated with cell proliferation and are activated by IGF-I 
receptor (27,147).  C-fos and c-jun being nuclear transcription factors, likely mediate 
some of the protein synthesis effects of IGF-I receptor.      
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IGF-I and insulin have both shared and unique actions.  Administration of IGF-I 
increases whole body protein metabolism by increasing protein synthesis and inhibiting 
proteolysis (63).  These actions are distinct from insulin, which acts primarily to inhibit 
proteolysis.  This evidence suggests that IGF-I acts primarily through the IGF-I receptor 
specifically as opposed to the insulin receptor in muscle.  Yet, IGF-I does enhance 
glucose uptake into muscle (85) which could be mediated by the insulin or IGF-I 
receptor.  Indeed, IGF-I has been used as an adjunctive therapy in patients who are 
insulin resistant to lower plasma glucose levels (134,188). 
The role of IGF-I in muscle development is exemplified by the studies in mice in 
which expression of myogenin has been knocked out, in that they show the same result as 
when IGF-I is knocked out i.e. no functional muscle development (78,117).  The opposite 
approach of transgenic animals expressing IGF-I, found muscle growth to be 30% above 
normal when IGF-I was expressed at 50% above control values (137).  Additionally DNA 
content increased in these muscles.  In muscle, IGF-I has been shown to increase amino 
acid uptake (126), suppress proteolysis (8), increase thymidine incorporation (66), 
stimulate myogenic differentiation(53), and stimulate myogenesis (187).  Even though, 
IGF-I unlike other mitogenic factors, will stimulate both proliferation and differentiation 
of muscle cells in culture (158) it does not stimulate differentiation while it is stimulating 
proliferation (46).  There is a temporal separation between these effects.  This may be 
made possible due to the versatile intracellular signaling of the IGF-I receptor.  IGF-I 
treatment of muscle cells results initially in a proliferative response during which 
expression of myogenic factors are inhibited, followed by stimulation of differentiation 
accompanied by down regulation of proliferative signals (54). 
 - 88 - 
Transgenic mice over expressing the IGF1 gene show enhanced myotube 
formation as well as increased mRNA levels of myogenic factors Myo D and myogenin 
and elevated mRNA for contractile proteins (28).  These mice with a 47-fold increase in 
IGF-I had hypertrophy of all myofiber classes with no increase in body weight or 
circulating IGF-I concentrations (28).  In addition, autocrine expression of IGF-I has been 
shown to contribute to myotube formation in embryo (73).  Autocrine secretion of IGF-I 
facilitates muscle regeneration after injury in normal and hypophysectomized rats 
(88,195).  It has been shown that IGF1 mRNA and protein levels increase during muscle 
regeneration (111).  Viral mediated over expression of IGF-I in mouse skeletal muscle 
has been shown to block the age related loss of skeletal muscle mass and strength.  
Furthermore, the IGF-I expression completely prevented the significant loss of the fastest 
most powerful type IIb muscle fibers seen in uninjected controls (11).  Transgenic mice 
over expressing IGF-I in muscle demonstrate protection from the normal loss of muscle 
mass and strength during senescence(137).  Additionally, these same transgenic mice 
display significantly improved muscle regeneration over control mice when muscle 
damage is induced via cardiotoxin (137).  The aged transgenic mice in this study display 
muscle characteristics similar to or better than younger control mice. 
It has also been demonstrated that muscle innervation may be improved in 
animals over expressing IGF-I.  In transgenic mice, skeletal muscle expressing IGF-I 
prevented aging alterations in the neuromuscular junction, preserved spinal cord motor 
neuron innervation of muscle, and decreased the loss of type IIb muscle fibers (127).  
Additionally, Rabinovsky reported that transgenic mice over expressing skeletal muscle 
IGF-I have accelerated muscle and motor neuron regeneration after sciatic nerve crush 
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injury (159).  The regeneration or preservation of neural innervation will likely be a 
causative factor in preventing muscle strength and mass loss with age. 
 Circulating IGF-I and exercise:  IGF-I is produced by various tissues including 
muscle, however, 98% of the circulating form of IGF-I is produced in the liver.  Several 
studies have examined this form of IGF-I in relation to exercise.  Cappon et al., (23) first 
demonstrated that 10 min of above-lactate threshold cycle ergometer exercise studied in 
10 subjects (age 22-35 yr) showed a small but significant increase in circulating IGF-I 
levels very briefly after exercise but this increase was only evident until 20 minutes after 
exercise while blood was sampled up to 24 hours after the exercise bout.  In a study of 
young men, 10 minutes of isolated forearm exercise showed a small but significant 
increase in circulating IGF-I, IGF-I BP3, and GH (43).  Indeed, it does seem that 
circulating GH does increase due to a bout of high intensity exercise (23,103,144).  
Nicklas et al. (144) reported an 18-fold increase in circulating GH immediately following 
a high intensity bout of RT in older men.  However, a ST program did not elicit a 
response in the resting circulating IGF-I levels when measured before and after the ST 
program (103,144).  Nindl et al. (145) examined the effect of a high intensity ST bout on 
circulating levels of IGF-I, IGF binding protein 2 (BP-2) and BP-3, and the acid labile 
subunit (ALS) immediately following ST and continuously (every hour) for 24 hours 
after.  They reported no change in total or free IGF-I protein immediately after exercise 
or the 24 hours post.  However, small but significant changes were observed in BP-2 and 
-3 and ALS.  The authors concluded that circulating IGF-I does not change with exercise, 
but that small changes in the IGF-I system may modulate its effects.  Two studies 
demonstrated an increase in muscle IGF-I with no change in circulating levels in 
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response to exercise (9,42).  Eliakim et al. (42) used 5 days of high intensity aerobic 
training in rats to analyze the change in circulating IGF-I compared to muscle.  After 5 
days it was found that the exercised rats increased muscle IGF-I protein levels 
significantly but neither the control nor exercise group increased circulating levels of 
IGF-I protein or IGF-I mRNA in muscle.  In a study examining the different responses to 
concentric versus eccentric exercise, it was reported that eccentric exercise acutely 
increased (62%) IGF1 mRNA, 48 hours after the bout of training with no change in 
circulating levels of IGF-I (9).  It can be concluded from these studies that circulating 
IGF-I levels are likely to play a minimal role in the response to exercise, but that locally 
expressed IGF-I impact is more dramatic.  The exact time course of the change in muscle 
IGF1 gene expression and protein translation will require further study. 
 The importance of locally produced IGF-I versus the circulatory form in muscle 
has been exemplified in several studies.  As mentioned previously, exogenous 
administration of GH may lead to an increase in muscle mass, but does seem to affect 
muscle protein synthesis or consistently affect muscle strength (220).  A study by Welle 
et al. injected a single dose of GH into elderly men and women and reported a significant 
increase in circulating levels of IGF-I, but no increase in the IGF-I mRNA in skeletal 
muscle (218).  Futhermore, it was demonstrated that liver specific deletion of the IGF1 
gene produced mice that lacked the circulating form of IGF-I yet displayed normal 
growth (192).  Thus, suggesting that the circulating endocrine form of IGF-I may not be 
important for muscle growth or maintenance in humans. 
Autocrine/Paracrine role of IGF-I in aging muscle:  Circulating levels of GH 
and IGF-I and muscle expression levels of IGF-I decrease with age (215).  The decline 
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begins in the thirties resulting in a 40 % decrease by the eighties.  This decrease in 
circulating levels of IGF-I specifically is thought to be a causal factor in the decline in 
muscle function that occurs with aging.  Additionally the autocrine/paracrine form of 
IGF-I produced by muscle is reduced with age, which is adding to or causing the decline 
in muscle function that occurs with aging. 
 The IGF1 gene can express multiple isoforms depending on the tissue of origin in 
addition to the stimulus.  Alternative splicing of mRNA derives these isoforms of the 
IGF1 gene.  The predominant circulating form of IGF-I is produced by the liver due to 
GH stimulation and has been termed IGF-1Eb.  The 1Eb isoform is produced utilizing the 
exon two promoter and therefore does not contain exon one.  The muscle expresses two 
known isoforms of the IGF1 gene when it is subjected to stretch or mechanical 
stimulation.  The first isoform is termed IGF-1Ea (182) and is initiated at the exon 1 
promoter similar to the liver form, yet in 1Ea, exon 5 is removed by alternative splicing.  
Overexpression of this isoform by transgenic mice has shown pronounced muscle 
hypertrophy (137).  Additionally older animals showed signs of protection against the 
normal loss of muscle mass associated with aging (137).  It was concluded that 
overexpression of this isoform of IGF1 could preserve muscle architecture and the age-
independent regenerative capacity of muscle. 
 The third IGF1 isoform is a splice variant resulting from a novel splice acceptor 
site in the intron preceding exon 6 and is generated in muscle subjected to stretch and 
overload (225).  This isoform has been termed mechano-growth factor (MGF) or IGF-
1Ec due to its expression by mechanical stimulation.  Structurally, the MGF mRNA 
differs from its liver counterpart because of the presence of a 49-base pair insert on the 
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carboxyl end of the protein, which is derived from exon 5 of the IGF1 gene.  It is not 
glycosylated, therefore, it is expected to have a shorter half-life than the liver IGFs.  MGF 
is thus likely to be designed to act in an autocrine/paracrine, rather than systemic, mode 
of action.  Yang et al. (225) were the first to demonstrate the up regulation of MGF in 
response to muscle stimulation.  In this model, rabbit muscle was subjected to stretch by 
immobilization and mechanical stimulation both of which produced the response of 
upregulating the MGF isoform.  Further work supported the findings of Yang et al. (124) 
when it was demonstrated that electrical stimulation and stretch resulted in an even 
greater increase in MGF and IGF-1Ea than stretch alone.  Since then, studies have shown 
that the MGF isoform of IGF-I can be upregulated in humans in response to ST.  
Bamman et al. (9) demonstrated an increase of 62% in muscle IGF-I in response to a 
single bout of eccentric ST while concentric training produced a similar increase it did 
not reach statistical significance.  This is not surprising because it is eccentric exercise 
that is known to cause more muscle damage than concentric and eccentric is thought to 
be necessary for muscle growth.   
To isolate the IGF-I isoforms, Psilander et al. (156) measured IGF-I mRNA levels 
in six young men at 1, 2, 6, 24, and 48 hours after a single bout of ST.  They found a 
decrease in IGF-IEa mRNA and no change in IGF-IEbc.  The small sample size and 
inability to distinguish between IGF-IEb and c may explain their null findings.  Fiatarone 
et al. (49) demonstrated a 500% increase in IGF-I expression in frail elders after one bout 
of ST however they did not isolate isoforms nor did they compare the results to a younger 
group.  To examine the possible age related response, Owino et al. (150) used synergistic 
muscle ablation to overload muscle in young and old rats.  They reported an increase in 
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IGF-I receptor in the young but not old rats and a dramatic increase in IGF-Ic (MGF) in 
the young with a small increase in MGF the old rats.  The MGF mRNA increase 
continued for three days in the young rats but plateaued after one day in the old rats.  To 
examine this relationship in humans a study of older (70-82) and younger men (25-36), 
Hameed et al. (71) measured muscle levels of IGF-1Ea and MGF before and after a bout 
of high intensity ST.  There was no difference between the young and old groups before 
the ST bout.  However, the biopsy taken 2.5 hours after the ST bout revealed an increase 
in MGF in the younger muscle but no change in the older muscle.  No change was 
observed in the expression levels of IGF-1Ea after the bout of ST in either group.  These 
studies suggest that the older muscle may have reduced capacity to be stimulated by a 
bout of ST.  However, in a more recent study, Hameed et al. (72) demonstrated in 17 
elderly men that 5 weeks of ST (24 hours after the last ST bout) would increase muscle 
MGF ~170% due to the ST, while exogenous supplementation of GH alone showed no 
effect on MGF.  Additionally they showed that ST had no effect on circulating levels of 
IGF-I 24 hours after the ST bouts. 
 It is clear that local expression of IGF-I is induced by ST and it is likely that IGF-
I is mediating many of the hypertorphic effects observed in skeletal muscle.  Yet as 
previously mentioned there is significant variability seen in the strength and hypertrophic 
response of muscle to ST.  Additionally, there is dramatic variability seen in the incresase 
in IGF-I that occurs in response to ST.  Hameed et al. (72) demonstrated that in young 
individuals, the increase of IGF-I in response to ST was 2 – 864%.  Furthermore, they  
demonstrated an average ~500% variation seen in elderly muscle in response to ST (72).  
Fiatarone et al. (49) reported greater than 500% variation in IGF-I expression in frail 
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elders following a bout of ST.  It would seem likely that genetics could be affecting this 
response.  Indeed, circulating levels of IGF-I have been shown to be almost completely 
under genetic control in healthy twin children and variability in circulating levels in the 
elderly has been estimated to be ~63% under genetic control (80,92).  To date no studies 
have examined the heritability of IGF1 muscle expression.  An autosomal genome wide 
search for genes related to fat free mass (FFM) and its changes after exercise training 
revealed that a polymorphism in the IGF1 promoter (192 allele) displayed significant 
linkage with changes in FFM (25).  Additionally, this same polymorphism displayed 
association and linkage with baseline FFM and the change in FFM due to exercise 
training (198).  The combined information from the studies of twins and circulating levels 
of IGF-I and the variable response of IGF1 amongst subjects who have undergone s 
similar muscular stimulus suggest that variation in IGF-I protein levels are under genetic 
control.  Additionally, the genome-wide scans, linkage, and association studies suggest 
that a polymorphism near the IGF1 locus is affecting the FFM mass response to training, 
which is strongly influenced by IGF production.  Therefore, it seems likely that the IGF1 
promoter polymorphism will be associated with skeletal muscle phenotypes in relation to 
stimulus known to increase IGF1 expression levels.  Numerous studies have examined 
the role of this polymorphism on circulating levels of IGF-I and various indicators of 
disease risk yet none have examined muscle related phenotypes. 
IGF1 polymorphism:  The IGF1 polymorphism examined in the genome wide 
scan and most association studies is a CA dinucleotide repeat near the promoter region of 
the IGF1 gene in humans (216).  A similar CA repeat near a gene promoter region has 
been shown to alter gene expression in rats and humans (2,181).  Repeat sequences 
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account for at least 50% of the entire human genome sequence (105).  Commonly defined 
as a perfect or near-perfect sequence repeat of 1 – 5 bases, microsatellites are found in 
tandem repeat units of 10 – 30 repeats.  Alternating purine-pyrimidine nucleotides (i.e. 
CA) are one type of microsatellite and, other than SNP’s, microsatellites are the most 
variable component of the human genome. Three percent of the human genome consists 
of microsatellite repeats of which CA dinucleotides are the most common making up 
0.5% of the human genome (105).   The biologic function of repeat units has not been 
fully defined but a non-random distribution of repeats exists in the human genome 
suggesting an evolutionary importance. 
 A proposed function of some microsatellites is to regulate gene transcription. A 
disproportionate amount of these repeats are found in the promoter regions of genes in 
the human genome (189).  This along with their known ability to alter gene transcription 
and the binding affinity of nuclear transcription factors make them areas of likely 
functional importance.  B-DNA is the stable lower energy state of DNA.  Under 
physiological conditions, most DNA in a eukaryotic cell is in right-handed B-DNA form.  
However, alternating purine-pyrimidine repeats, such as in a microsatellite, have been 
shown to form left-handed Z-DNA (146,181).  Energy input is required to form Z-DNA 
and this has been shown to come from transcription initiation which negatively supercoils 
DNA thus stabilizing the Z-DNA conformation (221).  Some studies have shown that 
alternating nucleotides (such as in a microsatellite) may alter gene expression when the 
repeats are located in the promoter region of a gene.  Alternating purine-pyrimidine  
microsatellites in promoter regions have been reported to be involved in regulation of 
gene expression (93,140,189).  Khashnobish et al. (98) were the first to report in vivo 
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regulation of gene expression by a CA repeat unit of varying lengths in Podospora 
anserine.  Their results demonstrated that the number of CA repeats positively affects 
reporter gene expression.  In a study by Peters et al. (152), it was shown in vitro that a 
CA repeat polymorphism commonly found in the human population can affect gene 
expression depending on length.  This was the first study to show that microsatellite 
length polymorphisms that are commonly found in normal human population can alter 
gene expression.  Furthermore, they demonstrated that the CA repeat element might serve 
as a binding site for specific nuclear regulatory proteins.  Regulation of gene expression 
by varying lengths of CA repeats in the promoter region, as mentioned, or in introns has 
been shown to affect gene expression in rats and humans (2,26,181).   
The microsatellite polymorphism in the IGF1 gene is typically between 16 and 22 
CA repeats and is commonly referred to by the base pair length of the amplified DNA 
fragment (e.g. 192 bp). The 192 allele (19 CAs at nucleotide position 1087-1127 in the 
human IGF-1 DNA sequence Genbank accession number AY260957) in the IGF1 
promoter polymorphism has been examined in numerous contexts.  Genotyping of the 
microsatellite is typically separated into three groups, 192 homozygotes, 192 
heterozygotes, and non-carriers of the 192 polymorphism.  Whether the 192 
polymorphism is causally related to changes in IGF1 function is not known; yet, the 192 
polymorphism is the most prevalent allele in the majority of the populations studied to 
date.  Although the 192 allele is not proven to be functional, it has proven to be a 
potential marker for disease related phenotypes and possibly IGF-I expression levels as 
discussed below.  Its variation in the human population and demonstrated linkage with 
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skeletal muscle related phenotypes make it an ideal candidate polymorphism for directly 
examining its association with well-defined skeletal muscle phenotypes.   
Rosen et al. (177) first implicated this polymorphism with serum levels of IGF-I 
and BMD in a study examining older men and women (178).  It was reported that 192 
homozygotes had lower blood levels of IGF-I and in a group of older men, 192 
homozygotes made up a disproportionately large number of those with idiopathic 
osteoporosis (178).  The reports by Frayling et al. (58) and Rietveld et al. (169)  concur 
with Rosen’s findings of decreased blood levels of IGF-I in carriers of the 192 
polymorphism.  In a cross-sectional study of young men and women, Frayling et al. (58) 
reported that 192 carriers had decreased blood levels of IGF-I, although no other 
associations were found.  The study by Rietveld et al. (169)  of older men and women, 
reported an age- related decline in blood levels of IGF-I in 192 homozygotes.  In contrast 
to Rosen’s findings, consequent studies have demonstrated an association of this 
polymorphism with osteoporosis but have concluded that 192 non-carriers have lower 
IGF-1 blood levels and are more likely to be osteoporotic (99,171,214).  A longitudinal 
study by Missmer et al.,  (132) in middle-aged and older men and women reported a 
lower level of IGF-I in control subjects who were non-carriers of the 192 allele.  This 
study concluded that 192 carriers would have the highest circulating levels of IGF-I.  
Similarly, Vaessen et al. (214) concluded that non-carriers of 192 again, had decreased 
blood levels of IGF-I and an increased risk for type II diabetes and myocardial infarction.  
Further support for 192 carriers having the highest circulating levels of IGF-I come from 
a study in Korean women; Kim et al. (100) reported the 192 homozygotes as having the 
highest blood levels of IGF-I.   
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Some reports have concluded that the 192 allele has no effect on blood levels of 
IGF-I or only has an effect when combined with oral contraceptive use (89,230).  Yet 
both of these studies found an association with a measured phenotype, breast cancer, or 
the interaction of blood levels, oral contraceptive use, and the 192 allele.  There have 
been two additional reports of the 192 allele showing no association with IGF-1 blood 
levels or any measured phenotype (3,34).  The study by Delellis et al., (34) examined 250 
adult women for association of the IGF-I microsatellite and breast cancer risk while the 
report from Allen examined older and younger men for association of blood levels of 
IGF-I and the IGF-I microsatellite polymorphism.  It was concluded by these studies that 
the 192 polymorphism is unlikely to be associated with IGF1 function.  Although 
conclusive determination of the effect of the 192 polymorphism from the aforementioned 
studies is difficult, it seems likely that the IGF1 192 polymorphism may affect skeletal 
muscle related phenotypes related to IGF1 expression being that both of the studies that 
have examined FFM reported a positive association.  
 If the 192 allele itself is not functional it would at least seem to be a valid marker 
for phenotypes related to IGF-I expression.  It is possible that the 192 polymorphism is in 
linkage disequilibrium with a functional polymorphism in the IGF1 gene.  Irrespective of 
the functionality there is yet to be a study examining the relationship of this 
polymorphism with the physiological phenotype most directly under the control of IGF-I, 
skeletal muscle.  A prospective intervention study is needed to address this issue.  The 
ideal intervention would be one known to stimulate both IGF-I expression and muscle 
hypertrophy.  It is known that the elderly suffer various health consequences from the 
loss of skeletal muscle function.  Furthermore, this loss can be offset or reversed through 
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a ST program.  Yet, there is significant inter-individual variability in the response to ST.  
With the heritability of skeletal muscle phenotypes and IGF-I, and the known relationship 
between the two, an association study examining skeletal muscle phenotypes with a gene 
related to IGF-I function could be extremely informative.  From the public health 
perspective, the greatest predictive benefit is derived from polymorphisms that are 
prevalent in the population.  The understanding of rare alleles (< 10% of the population) 
involved in complex phenotypes are unlikely to provide significant public health benefits.  
While the understanding of common polymorphisms would impact the greatest number 
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